top of page
Books

מאמרים אקדמיים שכתבתי

לאורך הקריירה כתבתי מגוון רחב של מאמרים מלומדים. מאמרים אלה משתרעים על קשת רחבה של נושאים הקשורים לסוכרת, ומציעים תובנות חשובות לאין ערוך לגבי מחקר חדשני, טיפולים חדשניים והתקדמות בתחום.

1)      Siegal T, Raz I, Polliack A. Nervous system involvement in malignant lymphoma. Harefuah 103(10):251-254,1982.

2)      Raz I, Haas H. Tuberculous axillary lymphadenitis - an unusual presentation. Tubercle 64:41-42,1983.

3)      Shaked A, Raz I, Gottehrer A, Romanoff H. Asymptomatic, highly vascularized superior mediastinal mass. Chest 86(4):621-622,1984.

4)      Raz I, Gottlieb D, Bar-On H. Acute dysphasia associated with hypoglycemia. Is J Med Sc 20(8):729-730,1984.

5)      Raz I, Katz M, Aram H, Haas H. Sporitrichoid Myobacterium marinum infection: Report of a ten year case. Int J Dermatol 23(8):554-555,1984.

6)      Raz I, Or R, Okon E, Leizerwitz R, Polliack A. Hairy cell leukemia: report of an unusual case with hepatomegaly due to a large vascular tumor of the liver, mediastinal mass and pleural effusion containing hairy cells. Acta Haematol 71(6):393-399,1984.

7)      Leitersdorf E, Israeli A, Raz I. Anorexia nervosa - an unusal presentation of the Plummer-Vinson syndrome. Int J Psych Med 14:343-346,1984.

8)      Weiss AT, Flugelman MY, Lewis BS, Raz I, Halon DA, Gotsman M. Isolated right ventricular infarction with ventricular tachyarrhythmia. Am Heart J 108(2): 425-426, 1984.

9)      Bialer M, Hussein Z, Dubrovsky J, Raz I, Abramsky O. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. Isr J Med Sci 20 (1): 46-49, 1984.

10)    Raz I, Polliack A. Coexistence of myelomonocytic leukemia and monoclonal gammopathy or myeloma. Simultaneous presentation in three patients. Cancer 53 (1): 83-85, 1984.

11)    Raz I, Shinar E, Polliack A. Pancytopenia with hypercellular bone marrow. A possible paraneoplastic syndrome in carcinoma of the lung. A report of three cases. Am J Hematol 16 (4): 403-408,1984.

12)    Raz I,  Bar-On H,  Kidron M,  Ziv E. Rectal administration of insulin. Isr J Med Sci 20 (2):173-175,1984.

13)    Raz I,  Bialer M,  Salame K,  Bar-On H. Comparative pharmacokinetic analysis of a novel sustained - release dosage from theophylline in humans. Eur J Clin Pharmacol 26 (3): 401-403, 1984.

14)    Hass H, Katz M, Raz I Isolation of the new species, Mycobacterium fallax in Israel. Isr J Med Sci 20 (11):1097-1098,1984.

15)    Raz I, Siegal T, Polliack A.  CNS involvement by non-Hodgkin's lymphoma: Response to a standard therapeutic protocol. Arch Neurol 41 (11): 1167-1171,1984.

16)    Raz I, Koffler M, Leitersdorf E, Bar-On H. Maintenance of ambulatory diabetic patients on subcutaneous insulin pump. Isr J Med Sci 20 (8): 731-735, 1984.

17)    Bialer M, Rubinstein A, Raz I, Abramsky O. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur J Clin Pharmacol 27 (4):501-503, 1984.

18)    Bialer M, Salame K, Raz I Effect of sustained release on the pharmacokinetics of theophylline in healthy subjects. Int J Clin Pharmacol Ther Toxicol 23 (12): 662-667,1985.

19)    Or R, Raz I, Polliack A. Hairly cell leukemia associated with carcinoma. Blut 50 (5): 299-301, 1985.

20)    Bialer M, Hussein Z, Raz I, Abramsky O, Herishanu Y, Pachys F. Pharmacokinetics of valproic acid in volunteers after a single dose study. Biopharm Drug Dispos 6(1):33-42,1985.

21)    Bialer M, Friedman M, Dubrovsky J, Raz I, Abramsky O.  Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans. Biopharm Drug Dispos 6 (4): 401-411,1985.

22)    Raz I, Fisher S, Israeli A, Gottehrer N, Chisin R, Kleinman Y. An unusual case of rheumatic pneumonia. Arch Int Med 145(6):1130-1131,1985.

23)    Rubinstein A, Bialer M, Frieman M, Raz I, Abramsky O. A combined approach to control   valproic acid - a kinetic and pharmacokinetic study. J Control Release 4:33-38,1986.

24)    Hussein Z, Bialer M, Friedman M, Raz I. Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies. Biopharm. Drug Dispos 8 (5): 427-435, 1987.

25)    Micaeli J, Lugassy G, Raz I, Uzieli B, Polliack A. Chronic lymphocytic leukemia and malignant lymphoma developing in patients with autoimmunity or other ill -defined immune stigmata: a review of the literature and report of an additional 9 cases. Hematol Rev 1: 291-310, 1987.

26)       Raz I, Leitersdorf E, KleinmanY. Acute bilateral brachial plexus neuritis associated with hypersensitivity vasculitis. A case report and review of the literature. Klin Wochenschr 63(14): 643-645,1985.

27)    Or R, Raz I, Rave D, Lichovitzki G, KleinmanY. Thymoma presenting as a superior vena cava syndrome remission following therapy. Klin Wochenschr 65(13): 617-619,1987.

28)    Caraco Y, Rave D, Raz I. Shigella sonnei myocarditis. Clin Cardiol 10(7): 423-424, 1987.

29)    Raz I. Hyperglycemia – its relation to diabetic neuropathy. Harefuah 112: 22-25, 1987 (Hebrew).

30)    Raz I. Diabetic nephropathy. Treatment with low protein diet. Harefuah 113 (3, 4): 75-77,1987 (Hebrew).

31)    Haas H, Raz I, Katz S. Tuberculous cervical lymphadenitis. Harefuah 112: 297-299,1987 (Hebrew).

32)   Arnon R, Raz I, Chajek-Shaul T, Berkman N, Field S, Bar-On H. Amiodarone pulmonary toxicity presenting as a solitary lung mass. Chest 93(2):425-427, 1988.

33)    Raz I, Soskolne V, Stein P.  Inluence of small group education sessions on glucose hemostasis in NIDDM.  Diabetes Care 11 (1): 67- 71, 1988.

34)    Raz I, Havivi E. Influence of chronic diabetes on tissue and blood cells status of zinc, copper and chromium in the rat. Diabetes Res 7 (1): 19-23, 1988.

35)    Raz I, Ben David J, Hussein Z, Samara E. Comparative phamacokinetic analysis of novel sustained-release dosage forms of pentoxifulline in healthy subjects. Int J Clin Pharmacol Ther Toxicol 26 (4): 206-208, 1988.

36)    Raz I, Hussein Z, Samara E, Ben-David J. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects. Int J Clin. Pharmacol. Ther. Toxicol 26 (5): 246-248, 1988.

37)    Raz I,  Rosenblit H,  Kark JD. Effect of moderate exercise on serum lipids in young men with low high density lipoprotein cholesterol. Arteriosclerosis 8 (3): 245-251, 1988.

38)    Raz I,  Hasdai D,  Seltzer Z,  Melmed RN. Effect of hyperglycemia on pain perception and on efficacy of morphine analgesia in rats. Diabetes 37 (9): 1253-1259, 1988.

39)    Raz I,  Adler JH,  Havivi E. Altered tissue content of trace metals in diabetic hyperinsulinaemic sand rats (Psammomys obesus). Diabetologia 31 (5): 329-333, 1988.

40)    Raz I, Havivi Y, Yarom R. Reduced negative surface charges on arterial endothelium of diabetic rats. Diabetologia 31 (8): 618-620, 1988.

41)    Raz I, Israeli A,  Rosenblit H,  Bar-On H. Influence of moderate exercise on glucose homeostatsis and serum testosterone in young men with low HDL-cholesterol level. Diabetes Res 9 (1): 31-35,1988.

42)    Caraco Y, Arnon R, Raz I. Atrioventricular block complicating acute streptococcal tonsilitis. Br Heart J 59(3): 389-390,1988.

43)    Caraco Y, Raveh D, Flugelman M, Raz I. Enhanced anticoagulation effect of acenocoumarol induced by amyodarone coadministration. Isr J Med Sci 24: 688-689, 1988.

44)    Israeli A, Matzner Y, Or R, Raz I. Gibenclamida causing thrombocytopenia and bleeding tendency: case reports and review of the literature. Klin Wochenschr 66(5): 223-224,1988.

45)    Raz I, Okon E, Chajek-Shaul T. Pulmonary manifestations in Behcet’s syndrome. Chest 95 (3): 585 - 589,1989 (Review).

46)    Raz I, Havivi E. Trace elements in blood cells of diabetic subjects. Diabetic Res 10 (1): 21-24,  1989.

47)    Raz I, Karsai D, Katz M. The influence of zinc supplementation on glucose homeostasis in NIDDM. Diabetes Res 11 (2): 73-79,1989.

48)    Zusman I, Yaffe P, Raz I, Bar-On H, Ornoy A. Effects of human diabetic serum on the in vitro development of early somite rat embryos. Teratology 39 (1): 85-92,1989.

49)    Kidron M, Krausz M, Raz I, Baron H, Ziv E. The absorption of insulin from dog                                                                 intestine is facilitated by bile acids. Tenside Surf Det 26: 352-354, 1989.

50)    Kennington AS, Hill CR, Craig J, Bogardus C, Raz I, Ortmeyer HK, Hansen BC,                              Romero G, Larner J. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. New Engl J Med 323 (6): 373-378,1990.

51)    Zurlo F, Lillioja S, Esposito-Del-Puente A, Nyomba BL, Raz I, Saad MF, Swinburn BA, Knowler WC, Bogardus C, Ravussin E. Low ratio of fat to cardohydrate oxidation as predictor of weight gain – study of 24-h RQ. Am J Physiol 259 (5 Pt 1): E650-657,1990.

52)     Harats D, Manny H, Raz I. Autoimmune hemolytic anemic in Gaucher’s disease. Klin Wochenschr 68(2):94-95,1990.

53)    Caraco Y, Arnon R, Raz I. Bethanechol induced cholinergic toxicity in diabetic neuropathy. DICP 24(3):327-328,1990.

54)    Harats D, Raz I, Lebensart P. Ultrasonographic appearance of well defined splenic       space-occupying lesions in Gaucher’s disease. Isr J Med Sci 26(3):168-170,1990.

55)   Nyomba BL, Freymond D, Raz I, Stone K, Mott DM, Bogardus C. Skeletal muscle glycogen synthase activity in subjects with non-insulin dependent diabetes mellitus after glyburide therapy. Metabolism 39 (11):1204-1210,1990.

56)    Raz I, Katz A, Spencer K. Ephinephrine inhibits insulin-mediated glycogenesis but enhances glycolysis in human skeletal muscle. Am J Physiol 260 (3 pt 1):E430-435,1991.

57)    Spencer MK, Katz I, Raz I. Ephinephrine increases tricarboxylic acid cycle intermediates  in human skeletal muscle. Am J Physiol 260 (3 pt 1): E436-439,1991.

58)    Katz A, Raz I, Spencer M K, Rising R, Mott MD. Hyperglycemia induces accumulation of glucose in human skeletal muscle. Am J Physiol 260 (4 pt 2): R698-703,1991.

59)    Maeda R, Raz I,  Zurlo F, Sommercorn J. Activation of skeletal muscle casein kinase II by insulin is not diminished in subjects with insulin resistance. J Clin Invest 87(3):1017-1022, 1991.

60)    McGuire MC, Fields RN, Nyomba B L, Raz I, Bogardous C, Tonks NK, Sommercorn J. Abnormal regulation of protein tyrosine phsophatase activities in skeletal  muscle of insulin-resistant humans. Diabetes 40(7):939-942,1991.

61)    Swinburn BA, Nyomba BL, Saad MF, Zurlo F, Raz I, Knowler WC, Lillioja S, Bogardus C, Ravussin E. Insulin resistance associated with  lower rates of weight gain in  Pima Indians. J. Clin Invest 88(1):168-173,1991.

62)    Havivi E, Bar On H, Reshef A, Stein P, Raz I. Vitamins and trace metals status in non insulin dependent diabetes mellitus. Int J Vit Nutr Res 61(4):328-333,1991.

63)    Kida Y, Raz I, Maeda R, Nyomba B L, Stone K, Bogardus C, Sommercorn J, Mott DM. Defective insulin response of phosphorylase phosphatase in insulin-resistant humans. J Clin Invest 89 (2):610-617,1992.

64)    Raz I, Levinger S, Maravi Y, Sigelmann N, Shananas M, Bursztyn M. Prevalence of glucose intolerance in young male Ethiopian immigrants. Isr J Med Sci 29 (6-7):347-350,1993.   

65)    Bursztyn M, Raz I. Blood pressure, glucose, insulin and lipids of young Ethiopian recent immigrants to Israel and in those residents for 2 years. J Hyperten 11 (4):455-459,1993.

66)                    Raz I, Chigier E, Rosenblit H, Mevorach R, Bursztyn M. Comparison of glucose   tolerance, lipids and blood pressure in young male Ethiopeans from two different immigrations – 1989 and 1991. Isr J Med Sci 29 (6-7): 351-354,1993.

67)    Bursztyn M, Ben-Ishay D, Shochina M, Mekler J, Raz I. Disparate effects of exercise training on glucose tolerance and insulin levels and on ambulatory blood pressure in hypertensive patients.J Hypertens 11(10):1121-1125,1993.

68)    Bursztyn M, Ben-Ishay D, Mekler J, Raz I. Chronic exogenous hyperinsulinemia without sugar supplementation: acute salt-sensitive hypertension without changes in resting blood pressure. J Hypertens 11(7): 703-707,1993.

69)    Sommercorn J, Fields R, Raz I, Maeda R. Abnormal regulation of ribosomal protein S6 kinase by insulin in skeletal muscle of insulin- resistant humans. J Clin Invest 91 (2):509-513, 1993.

70)    Bursztyn M, Raz I, Mekler J, Ben-Ishay D. Nitrendipine improves glucose tolerance and deoxyglucose uptake in hypertensive rats. Hypertension 23 (6 pt 2): 1051-1053,1994.

71)    Raz I, Hauser E, Bursztyn M.  Moderate exercise improves glucose metabolism in uncontrolled elderly patients with non-insulin-dependent diabetes mellitus. Isr J Med Sci 30 (10):766-770,1994.

72)    Bialer M,  Phara JZ,  Zuckerman S,  Raz I,  Abramsky O, Sterling J,  Ladkani D. Pharmacokinetic analysis of valdice dielhylcarbonate product of acid. Eur J Pharm Sci 2: 239-244,1994.

73)    Katz A,  Raz I.  Hexokinase kinetics in human skeletal muscle after hyperinsulinaemia, hyperglycemia and hyperepinephrinaemia. Acta Physio Scand 151 (4):527-530,1994.

74)    Raz I, Gilhar D, Hoffman A. Prolonged response to Glibenclamide in NIDDM patients in a normoglycemic state. Isr J Med Sci 30 (10):775-778,1994.

75)    Hoffman A, Fischer Y, Gilhar D, Raz I. The effect of hyperglycemia on the absorption of glibenclamide in patients with non-insulin dependent diabetes mellitus. Eur J Clin Pharmacol 47 (1):53-55,1994.

76)    Raz I. Exocrine insufficiency in transplanted pancreas imitating pancreatic rejection. Diabetes Care 17(7): 779-780,1994.

77)    Bursztyn M, Raz I, Ben-Ishay D. Blood pressure measurement method not                 responsible for results of Brands et al (Letter). Am J Hypertens 7(11):1033, 1994.

78)    Katz A, Raz I.  Rapid activation of glycogen synthase and protein phosphatase in human skeletal muscle after isometric contraction requires an intact circulation. Pflugers Arch 431(2):259-265,1995

79)    Bursztyn M, Raz I. Prediction of hypertension by the insulinogenic index in young Ethiopian immigrants. J Hypertens 13(1):57-61,1995.

80)    Philip M, Landau D, Segev Y, Weiss O, Raz I. Insulin-like growth factors (IGFs) and IGF-binding protein in diabetic kidney disease. Isr J Med Sci 31(12):712-716,1995.

81)    Weiss O, Anner H,  Nephesh I, Alayoff A, Bursztyn M,  Raz I. Insulin-like growth factor-I (IGF-I ) and IGF-I receptor gene expression in the kidney of the chronically hypoinsulinemic rat and hyperinsulinemic rat. Metabolism 44(8):982-986,1995.

82)    Friedlander M, Popovtzer MM, Weiss O, Nefesh I, Kopolovic J, Raz I. Insulin-like growth factor -1 (IGF-1)enhances recovery from HgC12-induced acute renal failure: the effects on renal IGF- 1, IGF -1 receptor and IGF-binding protein-1 mRNA. J Am Soc Nephrol 5 (10): 1782-1791,1995.

83)    Bursztyn M, Raz I. Blood pressure and insulin in Ethiopian immigrants: Longitudinal study. J Hum Hypertens 9 (4): 245-248, 1995.

84)    Meirow D, Yossepowitch O, Rosler A, Brezezinski A, Schenker JG, Laufer N, Raz I.  Insulin resistant and non-resistant polycistic ovary syndromes represent two distinct clinical and endocrinological subgroups. Hum Reprod 10 (8):1951-1956, 1995.

85)    Bursztyn M, Ben-Ishay D, Mekler J, Raz I. Chronic exogenous hyperinsulinemia accelerates the development of hypertension in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 22 (1): S28-29,1995.

86)    Bursztyn M, Ben-Ishay D, Mekler J, Raz I. Insulin induced renal dysfunction in regular Sabra rats. Clin Exp Pharmacol Physiol Suppl 22 (1): S32-33, 1995.

87)    Ornoy A, Zaken V, Abir R, Yaffe P, Raz I. Effects on rat embryos of culture in serum of women with gestational diabetes. Toxic in Vitro 9: 643-651, 1996.

88)    Ornoy A, Kimyagarov D, Yaffee P, Abir R, Raz I, Kohen R. Role of reactive oxygen species in diabetes induced embryotoxicity: studies on pre-implantation mouse embryos cultured in serum from diabetic pregnant women. Isr J Med Sci 32(11): 1066-1073, 1996.

89)    Leibowitz G, Tsur A, Chayen SD, Salameh M, Raz I, Cerasi E, Gross DJ. Pre-clinical Cushing’s syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. Clin Endocrino Oxf 44 (6): 717 - 722, 1996.

90)    Meirow D, Raz I, Yossepowitch O, Brzezinski A, Rosler A, Schenker JG, Berry EM. Dyslipidemia in polycystic ovarian syndrome: different groups, different etiologies? Hum Reprod 11(9):1848-1853, 1996.

91)    Cohen SE, Raz I, Safadi R. A patient with hypoparathyroidism, dysmorphic features and mental retardation. Eur J Med Res 1(5): 266-268,1996. (Review)

92)    Schulz-Knappe SE, Raz I, Safadi R. A patient with hypoparathyroidism, dysmorphic features and mental retardation. Eur. J Med Res 1: 266-268, 1996.

93)    Bursztyn M, Raz I, Mekler J, Ben-Ishay D. Effect of acute N-nitro-L-arginine methyl ester (L- NAME) hypertension on glucose tolerance, insulin levels and [3H] deoxyglucose muscle uptake. Am J Hypertens 10(6):683-686, 1997.

94)    Raz I,  Rubinger D,  Popovtzer M,  Gronback H,  Weiss O, Flyvbjerg A. Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotoc in diabetic rats. Diabetes 47(6):924-930,1998. Erratum in Diabetes 47(7): 1170, 1998.

95)    Rubinger D, Weiss O, Zarfati D, Popovtzer MM, Raz I. The effect of low dose octreotide administration on renal function and on gene expression of IGF-I axis components in experimental diabetes mellitus. J Endocrinol 159(1): 133-140, 1998.

96)    Mosseri M, Nahir M, Rozenman Y, Lotan C, Admon D, Raz I, Gotsman MS. Diffuse narrowing of coronary arteries in diabetic patients: the earliest phase of coronary artery disease. Cardiology 89 (2): 103-110, 1998.

97)    Averbukh E, Weiss O, Halpert M, Yanko R, Moshe R, Nephesh I, Flyvbjerg  A,  Yanko L, Raz I. Gene expression of insulin-like growth factor-I, its receptor and binding proteins in retina under hypoxic conditions. Metabolism 47 (11): 1331-1336, 1998.

98)   Symon Z,  Fuchs S,  Agmon Y, Weiss O, Nephesh I, Moshe R, Brezis M, Flyvbjerg, A,  Raz I. The endogenous insulin-like growth factor system in radiocontrast nephropathy. Am J Physiol 274 (3 Pt 2): F490-497, 1998.

99)   Cohen Y, Raz I, Merin G, Mozes B. Comparison of factors associated with 30 day mortality after coronary artery bypass grafting in patients with versus without diabetis mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. Am. J. Cardiol 81 (1): 7-11, 1998.

100)        Hirshberg B, Trelezky V, Raz I. Hypoglycaemia following pancreatic allograft transplantation.  J Int Med 243 (5):389-393, 1998.

101)        Lomnicky Y, Friedman M, Luria MY, Raz I, Hoffman A. The effect of the mode of administration on the hypolipidaemic activity of Niacin: Continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats. J Pharm. Pharmacol 50 (11): 1233-1239, 1998.

102)        Mumcuoglu KY, Ingber A, Gilead L, Stessman J, Friedmann R, Schulman H, Bichucher H, Ioffe-Uspensky I, Miller J, Galun R, Raz I. Maggot therapy for the treatment of diabetic foot ulcers (Letter) Diabetes Care 21:2030-2031, 1998.

103)        Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 44 (5):704-8, 1999.

104)        Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun 12 (2):121-129, 1999.

105)        Mumcuoglu KY, Ingber A, Gilad L, Stessman J, Friedman R, Schulman H, Bichucher H, Ioffe-Uspensky I, Miller J, Galun R, Raz I. Maggot therapy for the treatment of intractable wounds. Int J Dermatol 38(8):623-627, 1999.

106)        Datta U, Wexler ID, Kerr DS, Raz I, Patel MS. Characterization of the regulatory region of the human testis-specific form of the pyruvate dehydrogenase alpha-subunit (PDHA-2) gene. Biochim Biophys Acta 1447 (2-3):236-43, 1999.

107)        Sade K, Schwartz D, Wolman Y, Schwartz I, Chernichovski T, Blum M, Brazowski E, Keynan S, Raz I, Blantz RC, Iaina A. Time course of lipopolysaccharide-induced nitric oxide synthase mRNA expression in rat glumeruli. J Lab Clin Med 134(5): 471-7, 1999.

108)        Stern E, Raz I, Weitzman S. Prevalence of diabetes mellitus among workers in Israel: a nation-wide study. Acta Diabetol 36(4): 169-72, 1999.

109)        Keynan S, Hirshberg B, Levine-Iaina N, Wexler ID, Dahan R, Reinhartz E, Ovadia, H., Wollman Y, Chernihovskey T, Iaina A, Raz I. Renal nitric oxide production during the early phase of experimental diabetes mellitus. Kidney Int 58 (2): 740-7, 2000.

110)        Shpichinetsky V, Raz I, Friedlander Y, Goldschmidt N, Wexler ID, Ben-Yehuda A, Friedman G. The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. J Nutr 130 (10): 2493-7, 2000.

111)        Raz I, Wexler ID. Biomedical research in Israel: does it have a future? Isr Medical Assoc J 2 (7): 495-8, 2000.

112)        Averbukh E, Halpert M, Yanko R, Yanko L, Peer J, Levinger S, Flyvbjergh A, Raz I. Octreotide a somatostatin analogue fails to inhibit hypoxia-induced retinal neovascularisation in the neonatal rat. Int J Exp Diabetes Res 1 (1):39-47, 2000.

113)        Stepensky D, Friedman M, Srour W, Raz I, Hoffman A. Preclinical evaluation of pharmacokinetic – pharmacodynamic rationale for oral CR metformin formulation. J Control Release 71 (1):107-15, 2001.

114)        Bursztyn M, Flyvbjerg A, Weiss O, Mekler J, Raz I. Atrophy or hypertrophy in chronic renal ischemia: roll of the IGF-I system. Am J Hypertens 14 (12): 1211-1218, 2001.

115)        Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta–cell function in new- onset type 1 diabetes by specific immunomodulation with heat shock protein peptide (Diapep 277): a randomized, double-b phase II trial. Lancet 358 (9295):1749-53, 2001.

116)        Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Polh M, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 345(12):851-860, 2001.

117)        Wainstein J, Metzger M, Wexler ID, Cohen J, Raz I. The use of continuous insulin delivery systems in severely insulin-resistant patients. Diabetes Care 24 (7):1299, 2001.

118)        Raz I. Editor's Foreword. Diabetes Obes Metab 3 suppl 1:1-2, 2001.

119)        Wainstein J, Metzger M, Minuchin O, Harmann I, Cohen Y, Jaffe A, Raz I. Pump treatment for severely insulin resistant diabetic patients (Letter). Diabetes Care 24: 7 1299, 2001.

120)        Metzger M, Leibowitz G, Wainstein J, Glaser B, Raz I. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 25 (7): 1185-91, 2002.

121)       Khamaisi M, Flyvbjerg A, Haramati Z, Raz G, Wexler ID, Raz I. Effect of mild hypoinsulinemia on renal hypertrophy: growth hormone/insulin –like growth factor I system in mild streptozotocin diabetes. Int J Exp Diabetes Res 3 (4):257-64, 2002.

122)        Tepensky D, Friedman M, Raz I, Hoffman A. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 30(8):861-8, 2002.

123)        Khamaisi M, Raz I. Diabetes epidemic and the thrifty gene. Isr Med Assoc J 4 (9):720-721, 2002.

124)       Raz I, Wexler I, Weiss O, Flyvbjerg A, Segev Y, Rauchwerger A, Raz G, Khamaisi M. Role of insulin and the IGF system in renal hypertrophy in diabetic Psammomys obesus (sand rat).Nephrol Dial Transplant 18 (7):1293-8, 2003.

125)        Khamaisi M, Schrijvers BF, De Vriese AS, Raz I, Flyvbjerg A. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 18 (8):1427-30, 2003.

126)        Raz I, Rosengarten Y, Carasso R. Correlation study between conventional medical diagnosis and the diagnosis by reflexology (non-conventional). Harefuah 143(8-9):600-605, 646, 2003. (Hebrew)

127)        Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury Pl, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial (IDNT) of Patients with Type 2 diabetes and overt nephropathy.  Ann Inter Med 138 (7):542-549, 2003 [Summary for patients in Ann Inter Med. 138(7):143, 2003]

128)       Roth A, Kalter-Leibovici O, Kerbis Y, Tenenbaum-Koren E, Chen J, Sobol T, Raz I. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol 26 (1):25-30, 2003.

129)        Khamaisi M, Wainstein J, Hancu N, Milicevic Z, Raz I. Association of hyperglycemia and insulin with diabetic cardiovascular complications. Isr Med Assoc J 5 (2):116-9, 2003.

130)        Shafrir E, Raz I. Diabetes: mellitus or lipidus? Diabetologia 46 (3):433-40, 2003.

131)        Shafrir E, Raz I. Diabetes: mellitus or lipidus? Author's reply. Diabetologia 46 (11):1587, 2003.

132)        Gronbaek H, Tanos V, Meirow D, Peretz T, Raz I, Flyvbjerg A. Effects of tamoxifen on insulin –like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. Anticancer Res May- Jun 23 (3C):2815-20, 2003.

133)        Bursztyn M, Podjarny E, Dahan R, Raz I, Bernheim J. Insulin-induced hypertension, L-arginine, and endothelial nitric oxide synthase in pregnant rats. Hypertens Pregnancy 22 (3):267-74, 2003.

134)        Khamaisi M, Wexler ID, Shrha J, Strojek K, Raz I, Milicevic Z. Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities. Isr Med Assoc J 5 (11):801-6, 2003.

135)        Milicevic Z, Raz I. Interventions in diabetic patients after myocardial infarction. Acta Diabetol. 40 Suppl 2:S348-53, 2003.

136)        Cernea S, Hancu N, Raz I. Diet and coronary heart disease in diabetes. Acta Diabetol, 40 suppl 2:S389-400, 2003.

137)        Raz I, Mouritzen U, Vaz J, Hershkovitz T, Wainstein J, Boehm I. Addition of biphasic insulin aspart 30 to rosiglitaxone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther 25 (12):3109-23, 2003.

138)        Elazary AS, Lador N, Shauer A, Meir K, Pollak A, Wolf DG, Raz I, Leitersdorf E, Mevorach, D. Tongue necrosis and pericarditis. Lancet 363 (9413):948, 2004.

139)        Keynan S, Khamaisi M, Dahan R, Barnes K, Jackson CD, Turner AJ, Raz I. Increased expression of endothelin-converting enzyme- 1c isoform in response to high glucose levels in endothelial cells. J Vasc Res 41(2):131-40, 2004.

140)        Abdul-Ghani MA, Sabah M, Minuchin O, Vardi P, Raz I, Wainstein J. Primary prevention of type 2 diabetes: how do we do it? Isr Med Asso J. 6 (5):305-7, 2004.

141)        Tsur A, Harman-Boehm I, Wainstein J, Raz I. Primary care for type 2 diabetes: Harefuah 143(5); 353-354, 2004. (Hebrew)

142)        Anis Y, Leshem O, Reuveni H, Wexler I, Ben Sasson R, Yahalom B, Laster M, Raz I, Ben- Sasson S, Shafir E, Ziv E. Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes. Diabetologia 47(7):1232-1244, 2004.

143)        Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F, Goldhaber S, Lewish EJ, Pfeffer MA. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl 92:S50-55, 2004. Review

144)        Eldor R, Raz I, Ben Yehuda A, Boulton AJ. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med 21(11):1161-1173, 2004. Review.

145)        Raslova K, Boboev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 666(2):193-201, 2004.

146)        Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther 26(12): 2084-2091, 2004.

147)        Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 21(1):3-14, 2005. Review.

148)        Fujioka K, Brazg RL, Raz I, Bruce S, Joyal S, Swanink R, Pans M. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment wit diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab 7(1):28-39, 2005

149)        Raz I, Eldor R, Naparstek Y. Immune modulation for prevention of type 1 diabetes mellitus. Trends Biotechnol 23(3):128-134, 2005. Review.

150)        Milicevic Z, Raz I, Strojek K, Skrha J, Tan MH, Wyatt JW, Beattie SD, Robbins DC; HEART2D Study. Hyperglycemia and its effect after acute myocardial infarction of cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. J Diabetes Complications 19(2):80-87, 2005.

151)        Abdul-Ghani MA, Sabbah M, Muati B, Dakwar N Kashkosh H, Minuchin O, Vardi P, Raz I. High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. Isr Med Assoc J 7(3):143-147, 2005.

152)        Eldor R, Raz I. Lipids and glucose in type 2 diabetes: What about the beta-cell and the mitochondria? Response to Boden and Laakso. Diabetes Care 28(4):985-986, 2005. (Author reply, 986-987).

153)        Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M, Segev Y, Weksler-Zangen S, Raz I, Yagil Y. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. Diabetes 54(5):P1487-1496, 2005.

154)        Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Dose-response relationship of oral insulin spray in healthy subjects. Diabetes Care 28(6):1353-1357, 2005.

155)        Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 16(7):2170-2179, 2005.

156)        Hillel J, Gefel D, Kalman R, Ben-Ari G, David L, Orion O, Feldman MW, Bar-On H, Blum S, Raz I, Schaap T, Shpirer I, Lavi U, Shafrir E, Ziv E. Evidence for a major gene affecting the transition from normoglycaemia to hyperglycaemia in Psammomys obesus. Heredity 95(2):158-165, 2005.

157)        Eldor R, Stern E, Milicevic A, Raz I. Early use of insulin in type 2 diabetes. Diabetes Res Clin Pract Suppl 1:S30-35, 2005.

158)        Kalter-Leibovici O, Wainstein J, Ziv A, Harman-Boehm I, Murad H, Raz I; Israel Diabetes Research Group (IDRG) Investigators. Clinical, socioeconomic and lifestyle parameters associated with erectile dysfunction among diabetic men. Diabetes Care 28(7):1739-1744, 2005.

159)        Raz I. Complex impact of obesity on type 2 diabetes. Isr Med Assoc J 7(6):402-403, 2005.

160)        Raz I. Peace building through health in Israel and Palestine. Lancet 366(9479):26. Letter, 2005.

161)        Wainstein J, Metzger M, Boaz M, Minuchin O, Cohen Y, Yaffe A, Yerushalmy Y, Raz I, Harman-Boehm I. Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabet Med 22(8):1037-1046, 2005.

162)        Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, Chow CC, Shaban J. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clin Ther 27(9):1432-43, 2005.

163)        Eldor R, Cohen IR, Raz I. Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus. Int Rev Immunol 24(5-6): 327-39, 2005.

164)        Cernea S. Kidron M, Wohlgelernter J, Raz I. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. Clin Ther 27(10):1562-70, 2005.

165)        Khamaisi M, Keynan S, Bursztyn M, Dahan R, Reinhartz E, Ovadia H, Raz I. Role of renal nitric oxide synthase in diabetic kidney disease during the chronic phase of diabetes. Nephron Physiol 102(3-4):72-80, 2006.

166)        Abdul-Ghani MA, Sabbah M, Kher J, Minuchin O, Vardi P, Raz I. Different contributions of insulin resistance and beta-cell dysfunction in overweight Israeli Arabs with IFG and IGT. Diabetes Metab Res Rev 22(2):126-30, 2006.

167)        Knobler H, Benderly M, Boyko V, Behar S, Matas Z, Rubinstein A, Raz I, Wainstein J. Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose. Eur J Endocrinol 154(1):87-92, 2006. 

168)        Cernea S, Raz I. Noninjectable methods of insulin administration.  Drugs of Today 42(6):405-424, 2006

169)        Szalat A, Raz I. Metabolic syndrome and microangiopathy. Isr Med Assoc J 8(6):424-425, 2006

170)        Weiss R, Raz I. Focus on childhood fitness, not just fatness. Lancet 368(9532):261-262, 2006.

171)        Raz I: Introduction. Diabets Res Clin Pract 74 Suppl 1:S1-2, Epub 2006

172)        Eldor R, Raz I: Lipotoxicity versus adipotoxicity-The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes. Diabetes Res Clin Pract 74 Suppl 1:S3-8. Epub 2006

173)        Tsur A, Harman-Boehm I, Buchs AE, Raz I, Wainstein J: The guidelines for the diagnosis, prevention and treatment of type 2 diabetes mellitus – 2005. Harefuah 145(8):583-6, 630, 2006 (Hebrew)

174)        Ziegler D, Ametov A, Barinov A Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J. Samigullin R: Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 29(11):2365-70, 2006

175)        Elias D, Avron A, Tamir M, Raz I: DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. Ann NY Acad Sci 1079:340-4, 2006

176)        Cernea S, Raz I: Noninjectable methods of insulin administration. Timely Top Med Cardiovasc Dis10;E29, 2006 Review

177)        Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R, Cohen IR, Elias D. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 23:292-298, 2007

178)       Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, Elad S: Possible association between diabetes and bisphosphonate-realted jaw osteoneonecrosis. J Clin Endocrinol Metab 92(3):1172-5, 2007

179)        Yagil C, Barkalifa R, Sapojnikov M, Wechsler A, Ben-Dor D, Weksler-Zangen S, Kaiser N, Raz I, Yagil Y: Metabolic and genomic dissection of diabetes in the Cohen rat. Physiol Genomics April 24;29(2):181-192, 2007

180)        Ryden L, Stankl E, Barnik M, Vanden Berghe G, Betteridge J, de Boer MJ, Cosentino F, Honsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregro K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Chabonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro Pf, Parhofer K, Pyorala K, Raz I, Schernthaner G, Volpe M, Wood D: Task Force on Diabetes and Cardiovascular Diseases  of the European Society of Cardiology (ESC); European Association for the Study of Diabetes. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28(1):88-136, 2007

181)        Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, Raz I: Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev Oct:23(7):551-558, 2007

182)       Weiss R, Yegorchikov Y, Shusterman A, Raz I: Noninvasive continuous glucose monitoring using photoacoustic technology-results from the first 62 subjects. Diabets Technol Ther 9(1):68-74,  2007

183)        Raz I: Sitagliptin: a viewpopint by Itamar Raz. Drugs 67(4):598-599, 2007

184)       Khamaisi M, Sondergaard M, Segev Y, Dagnaes-Hansen F, Jensen TG, Landau D, Raz I, Flyvbjerg A: Differential effects on kidney and liver growth of a non-viral hGh-expression vector in hypophysectomized mice. Growth Horm IGF Res Aug;17(4):279-287, 2007

185)        Elinav H, Wolf Z, Szalat A, Bdolah-Abram T, Glaser B, Raz I, Leibowitz G: In-hospital treatment of hyperglycemia: effects of intensified subcutaneous insulin treatment. Curr Med Res Opin Apr;23(4):757-765. 2007

186)        Weiss R, Raz I: Diabetic ketoacidosis--beware of cerebral edema!

Harefuah 146(12):939, 99, 2007 (Hebrew)

187)       Raz I, Eldor R: New treatments for diabetes. N  Engl J Med May 24; 356(21):2222, author reply 2222-2223, 2007

188)        Bakris Gl, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I: Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int Oct;72(7): 879-885, 2007

189)        Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R: Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology Jan;54(1):244-249, 2008

190)        Shai I, Wainstein J, Harman-Boehm I, Raz I, Fraser D, Rudich A, Stampfer MJ: Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: a multicenter, randomized, clinical intervention trial. Diabetes Care Dec;30(12):3011-3016, 2007

191)        Naor D, Nedvetzki S, Walmasley M, Yayon A, Turley EA, Golan I, Caspi D, Sebban LE, Zick Y, Garin T, Karussis D, Assaya-Asherie N, Raz I, Weiss L, Slavin S, Golan I: CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann NY Acad Sci Sep;1110:233-247, 2007

192)        Weiss R, Niecestro R, Raz I: The role of sulodexide in the treatment of diabetic nephropathy. Drugs 67(18):2681-2696, 2007

193)        Heerspink HL, Greene T, Lewis JB, Raz I, Rohde RD, Hunsicker LG, Schwartz SL, Aronoff S, Katz MA, Eisner GM, Mersey JH, Wiegmann TB: for the Collaborative Study Group. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant Jun;23(6):1946-54, 2008

194)       Weksler-Zangen S, Raz I, Lenzen S, Jorns A, Ehrenfeld S, Amir G, Oprescu A, Yagil Y, Yagil C, Zangen DH, Kaiser N: Impaired glucose stimulated insulin secretion is coupled with exocrine pancreatic lesions in the Cohen diabetic rat. Diabetes  Feb;57(2):279-87, 2008

195)        Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M: Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.

                   Curr Med Res Opin 24(2):537-50, 2008

196)       Feder J, Blech I, Ovadia O, Amar S, Wainstein J, Raz I, Dadon S, Arking DE, Glaser B, Mishmar D: Differences in mtDNA haplogroup distribution among 3 Jewish populations alter susceptibility to T2DM complications. BMC Genomics. 29;9(1):198, 2008

197)       Khamaisi M, Raz I, Shilo V, Shina A, Rosenberger C, Dahan R, Abassi Z, Meidan R, Lecht S, Heyman SN: Diabetes and radiocontrast media increase endothelin converting enzyme-1 in the kidney. Kidney Int 74(1):91-100, Jul; 2008

198)       Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group: Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.  Diabetes Obes Metab 10(5):387-99, 2008. Epub 2008 Mar 18

199)       Bachrach G, Muster Z, Raz I, Chaushu G, Stabholz A, Nussbaum G, Gutner M, Chaushu S: Assessing the levels of immunoglobulins in the saliva of diabetic individuals with periodontitis using checkerboard immunodetection. Oral Dis. Jan;14(1):51-9, 2008

200)       de Zeeuw D, Raz I: Albuminuria: a great risk marker, but an underestimated target in diabetes. Diabetes Care 31 Suppl 2:S190-3, 2008. No abstract available.

201)       Milicevic Z, Raz I, Beattie SD, Campaigne BN, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M: Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 31 Suppl 2:S155-60, 2008

202)       Raz I, Weiss R: The Controversies in Obesity, Diabetes and Hypertension (CODHy) meeting: what is it all about?  Diabetes Care 31 Suppl 2:S111-2, 2008

203)       Sjolie Ak, Klein R, Porta M, Orchard T, Fuller J, Parving Hh, Bilous R, Chaturvedi N; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT_Protect 2): a randomized placebo-controlled trial. Lancet 372(9647): 1385-1393, Oct 18; 2008

204)       Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjolie AK; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomized, placebo-controlled trials. Lancet  372(9647):1394-1402, Oct 18;2008

205)       Feder J, Blech I, Ovadia O, Amar S, Wainstein J, Raz I, Dadon S, Arking DE, Glaser B,l Mishmar D. Differences in mtDNA haplogroup distribution among 3 Jewish populations alter susceptibility to T2DM complications. BMC Genomics 9:198, 2008

206)       Auryan S, Raz I. Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabets Obes Metab  10(12):1135-1156, Dec; 2008.

207)       Kjamaisi M, Dahan R, Hamed S, Abassi Z, Heyman SN, Raz I. Role of protein kinase C in the expression of endothelin converting enzyme-1. Endocrinology 150(3):1440-1449, Mar; 2009.

208)       Zigmond E, Zangen SW, Pappo O, Sklair-Levy M, Lalazar G, Zolotaryova L, Raz I, Ilan Y. Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. Am J Physiol Endocrinol Metab 296(1) E72-78, Jan; 2009.

209)       Keidar A, Abu Abeid S, Lieberman G, Bachrach R, Zacharovitch D, Raz I. Surgical treatment of morbid obesity. Harefuah 147(11):879-884, 940-941, 2008 (Hebrew)

210)       Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milievic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care  32(3):381-386, Mar; 2009

211)       Eldor R, Kassem S, Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev. May;25(4):316-20, 2009

212)       Eldor R, Raz I. The individualized target HbA1c: A new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud. 2009 Spring; 6(1)6-12. [Epub 2009 May 10]

213)       Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B. Effect of a local heating device on insulin and glucose pharmacokinetic profiles I an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther May;31(5):980-987, 2009

214)       Unnikrishnan AG, Tibaldi J, Hadley-Brown M, Krentz AJ, Ligthelm R, Damci T, Gumprect J, Gero L, Mu Y, Raz I. Practical guidance on intensification of insulin therapy with BIAsp30: a consensus statement. Int J Clin Pract  Nov; 63(11):1571-1577, 2009 [Epub 2009 Sep 19].

215)       Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RD, Skyler JS, Palmer JP. Challenges in developing endpoints for type1 diabetes intervention studies. Diabetes Metab Res Rev Nov 25(80): 694-704, 2009

216)       Dankner R, Chetrit A, Shanik MH, Raz I, Roth J. Basal-state hyperinsulinemia in healthy normoglycemic adults in predictive of type 2 diabetes over a 24-year follow-up: a preliminary report. Diabetes Care Aug;32(8):1464-1466, 2009

217)       Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract  Sep;63(9):1395-406, 2009

218)       Kassem SA, Raz I. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes Care Nov 32(Suppl 2) S337-S341, 2009

219)       Eldor R, Raz I. American Diabetes Association indications for statins in diabetes: is there evidence? Diabetes Care Nov 32(Suppl 2) S384-S391, 2009

220)       Raz, I. Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): dilemmas in clinical practice. Diabetes Care Nov 32 (Suppl 2):S149-50, 2009

221)       Nahmias A, Tamir O, Raz I, Wainstein J. In anticipation of patient participation. Isr Med Assoc J. 11(12):751-2, 2009

222)       Raz I. Relationship between blood glucose control and improved cardiovascular outcome after stent implantation in diabetic patients. Cardiology 116(1)48-50, 2010

223)       Pozzilli P, Leslie RD, Chan J, De Fronzo R, Monnier L, Raz I, Del Prato S. The A1C  and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 26(4):239-44, 2010

224)       Mizrahi M, Lalazar G, Adar T, Raz I, Ilan Y. Assessment of insulin resistance by a 13C glucose breath test: a new tool for early diagnosis and follow-up of high-risk patients. Nutr J 9:25, 2010

225)       Keidar A, Schweiger C, Raz I. New insight into old disease: potential treatment of type 2 diabetes mellitus by bariatric surgery. Harefuah 149(2):95-8, 2010 (Hebrew)

226)       Dankner R, Chetrit A, Murad H, Sela BA Frystyk J, Raz I, Flyvbjerg A. Serum adiponecti is associated with homocysteine in elderly men and women, and with 5, 10-methylenetetrahydrofolate reductase (MTHFR) in a sex-dependent manner. Metabolism  Dec;59(12):1767-74, 2010

227)       Glandt M, Raz I. Pharmacotherapy: ACCORD Blood pressure and ACCORD lipid: How low can we go? Nat Rev Endocrinol 6(9):483-4, 2010

 

228)       Stenlof K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin. Oct;26(10):2355-63, 2010

229)       Cernea S, Dobreanu M, Raz I. Prevention of type 1 diabetes: today and tomorrow. Diabetes Metab Res Rev. Nov;26(8):602-5, 2010

230)       Leibowitz G, Raizman E, Brezis M, Glaser B, Raz I, Shapira O. Effects of moderate intensity glycemic control after cardiac surgery. Ann Thorac Surg. Dec;90(6):1825-32, 2010

231)       Levin-laina N, Laina A, Raz I. The emerging role of NO and IGF-1 in early renal hypertrophy in STZ-induced diabetic rats. Diabetes Metab Res Rev Mar;27(3):235-243. doi: 10.1002/dmrr.1172, 2011

232)       Prota M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjolie AK;DIRECT Study Group. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials. Diabetologia Jun;54(6):1298-1303. Epub 2011 Jan 12

233)       Glandt M, Raz I. Present and future: pharmacologic treatment of obesity. J Obes. 2011:636181. Epub 2011 Feb 8

234)       Glandt M, Raz I. Analysis: accuracy performance of the Medtronic NexSensor for 6 days in an inpatient setting using abdomen and buttocks insertion sites. J Diabetes Sci Technol Mar 1;5(2):365-367, 2011

235)       Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care May;34 Suppl 2:S101-106, 2011

236)       Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care 34 Suppl 2:S264-271, 2011

237)       Raz I, Del Prato S. Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): outcome studies versus clinical experience in the treatment of diabetes. Diabetes Care 34 Suppl 2:S99-100, 2011

238)       Schroeder JE, Liebergall M, Raz I, Egleston R, Sussan GB, Peyser A, Eldor R.

Four by four; Simple glycemic control in an orthopedic surgery ward - a randomized prospective study of a four step intervention process. Diabetes Metab Res Rev. 2011 May 17. doi: 10.1002/dmrr.1217. [Epub ahead of print]

239)       Raz I, Ceriello A, Wilson PW, Battioui C, Su EW, Kerr L, Jones CA, Milicevic Z, Jacober SJ. Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia. Diabetes Care Jul;34(7):1511-3. Epub 2011 May 18. 2011

240)       Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovitz T, Packham DK, Lewis JB; for the Collaborative Study Group. Pyridorin in Type 2 Diabetic Nephropathy, J Am Soc Nephrol. 2011 Oct 27. [Epub ahead of print]

241)       Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC; for the Collaborative Study Group. Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy. J Am Soc Nephrol. 2011 Oct 27. [Epub ahead of print]

242)       Brito M, Ligthelm RJ, Boemi M, Kumar A, Raz I, Koblik T, Gao Y, Christiansen JS. Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement. Indian J Endocrinol Metab. 2011 Jul;15(3):152-60

243)       Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011 Nov;58(5):729-36. Epub 2011 Aug 26.

244)       Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB; for the Collaborative Study Group. Pyrodin in Type 2 Diabetic Neuropathy. J Am Soc Nephrol. 2011 Nov 10. [Epub ahead of print]

 

245)       Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Price DL, Chen R, Udell J, Raz I.  The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. Am Heart J. 2011 Nov;162(5):818-825.e6.

246)       Raz I, Eldor R. Rational therapy for Diabetes: Early recognition of adverse effects and avoidance of disruptive false alarms. Diabetes Metab Res Rev. 2011 Dec 15.doi:10.1002/dmrr.2265. [Epub ahead of print]

247)       Weksler-Zangen S, Mizrahi T, Raz I, Mirsky N. Glucose tolerance factor extracted from yeast: oral insulin-mimetic and insulin-potentiating agent: in vivo and in vitro studies. Br J Nutr. 2011 Dec 15:1-8. [Epub ahead of print]

248)       Raz I, Gallwitz B. The continuing need for drug development and clinical trials in type 2 diabetes and its complications: Introduction to the RDS Special Issue. Rev Diabet Stud. 2011 Fall;8(3):288-92. Epub 2011 Nov 10

249)       Raz I, Fonseca V, Kipnes M, Durrwell L, Hoekstra J,Boldrin M, Balena R. Efficacy and safety of taspoglutide monotherapy in drug-naïve type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes Care. 2012 Mar:35(3):485-487

250)       Udell JA, Scirica BM, Braunwald E, Raz I, Steg PG, Davidson J, Hirshberg B, Bhatt KL. Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. Clin Cardio.2012 Jul 3.doi: 10.1002/clc.22032. [Epub ahead of print]

251)       Raz I, Amiel SA, Alberti G, Shehadeh N, Del Prato S, Zimmet P, Cefalu WT. Global call for free academic movement for international dialogue. Diabetes Care. 2012 35(8):1631-2

252)       Dankner R, Chetrit A, Shanik MH, Raz I, Roth J. Basal state hyperinsulinemia in healthy normoglycemic adults heralds dysglycemia after more than two decades of follow up. Diabetes Metab Res Rev. 2012 Oct;28(7):618-24

253)       Tamir O, Wainstein J, Raz I, Shemer J, Heymann A. Quality of life and patient-perceived difficulties in the treatment of type 2 diabetes. Rev Diabet Stud.2012 Spring;9(1):46-54

254)       Raz I. Exogenous hyperinsulinemia and atherosclerosis in type 1 diabetic patients. J Diabetes Complications.2012 Nov 11 doi:pii: S1056-8727(12)00283-8. 10.1016/j.jdiacomp.2012.10.003. [Epub ahead of print]

255)       Eldor R, Raz I. Diabetes therapy-focus on Asia: second-line therapy debate: insulin/secretagogues. Diabetes Metab Res Rev.2012 Dec;28 Suppl 2:85-9.doi: 10.1002/dmrr.2358

256)       Mosenzon O, Raz I. Potential cardiovascular effects of dipeptidyl

peptidase-4 inhibitors in patients with type 2diabetes: current evidence and ongoing trials. European Heart Journal Supplements 2012 14 (Supplement B),

                B22–B29 doi:10.1093/eurheartj/sus003

 

257)       Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begrup K, Birkeland KI;NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013 Apr;36(4):858-64.doi.2337/dc12-1668. Epub 2013 Jan 22

258)       Livshits L, Srulevich A, Raz I, Cahn A, Barshtein G, Yedgar S, Eldor R. Effect of short-term hyperglycemia on protein kinase C alpha activation I human erythrocytes. Rev Diabet Stud. 2012 Summer-Fall;9(2-3):94-103.doi: 10.1900/RDS.2012.9.94. Epub 2012 Nov 15

259)       Dickman R, Dislov J, Boaz M, Ron Y, Beniashvili Z, Raz I, Baigel I, Niv Y, Wainstein J. Prevalence of symptoms suggestive of gastroparesis in a cohort of patients with diabetes mellitus. J Diabetes Complications. 2013 Mar 15:doi:pii:S1056-8727(13)00050-0.10.1016/j.jdiacomp.2013.02.004. [Epub ahead of print]

260)       Weksler-Zangen S, Jorns A, Tarsi-Chen L, Vernea F, Aharon-Hananel G, Saada A, Lenzen S, Raz I. Dietary copper supplementation restores beta-cell function of Cohen diabetic rats: a link between mitochondrial function and glucose-stimulated insulin secretion. Am J Physiol Endocrino Metab. 2013 May;304(10)E1023-34.doi: 10.1152/ajpendo.00036.2013. Epub 2013 Mar 19.

261)       Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, Steg PG, Davidson J, Ohman P, Price DL, Frederich B, Udell JA, Braunwald E, Bhatt DOL. Baseline characteristics of outpatient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR) – TIMI 53 Trila. Diabetes Metab Res Rev. 2013 Apr 6. Doi: 10.1002/dmrr.2413. Epub ahead of print

262)       Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs. 2013 Jun;18(2):245-58

 

 

263)       Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JC, Leiter LA, Leroith D, DeFronzo R, Cefalu WT. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care. 2013 Jun;36(6):1779-88

 

264)       Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013 Oct 3;369(14)1317-26

 

265)       Mosenzon O, Raz I. Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom? Diabetes Care. 2013 Aug;36 Suppl 2:S212-8

 

266)       Raz I. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013 Aug;36 Suppl 2:S139-44

 

267)       Del Prato S, Raz I. Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Diabetes Care. 2013 Aug;36 Suppl 2:S111-2

 

268)       Raz I, Mosenzon O. Early insulinization to prevent diabetes progression. Diabetes Care. 2013 Aug;36 Suppl 2:S190-7. doi: 10.2337/dcS13-201

 

269)       Smink PA, Miao Y, Eijkemans MJ, Bakker SJ, Raz I, Parving HH, Hoekman J, Grobbee DE, de Zeeuw D, Heerspink HJ. The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of Angiotensin Receptor Blockers. Clin Pharmacol Ther. 2014 Feb;95(2):208-15. doi: 10.1038/clpt.2013.191.

 

270)       Weksler-Zangen S, Aharon-Hananel G, Mantzur C, Aouizera T, Gurgul-Convey E, Raz I, Saada A. Interleukin-1β hampers glucose stimulated insulin secretion in Cohen diabetic rat islets through mitochondrial cytochrome c oxidase inhibition by nitric-oxide. Am J Physiol Endocrinol Metab. 2014 Jan 14. [Epub ahead of print]

 

271)       Pozzilli P, Raz I, Peled D, Elias D, Avron A, Tamir M, Eren R, Dagan S, Cohen IR. Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal. Diabetes Care. 2014 Jan 9. [Epub ahead of print]PMID: 24408401 [PubMed - as supplied by publisher]

 

 

272)       Pfützner A, Hermanns N, Funke K, Forst T, Behnke T, Bitton G, Nagar R, Raz I, Haak T. The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus. Curr Med Res Opin. 2014 Jan 17. [Epub ahead of print]PMID: 24392996 [PubMed - as supplied by publisher]

 

273)       Landau Z, Klonoff D, Nayberg I, Feldman D, Levit SB, Lender D, Mosenzon O, Raz I, Wainstaein J. Improved pharmacokinetic and pharmacodynamic profile of insulin analogs using InsuPatch, a local heating device. Diabetes Metab Res Rev. 2014 Mar 10. Doi: 10.1002/dmrr.2536. [Epub ahead of print]

 

 

 

274)       Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, Del Prato S, Leroith D, Schernthaner G, van Gaal L, Raz I. Insulin therapy in people with type 2 diabetes: opportunities and challenges. Diabetes Care. 2014 June;37(6):1499-508

 

 

275)       Raz I, Bhatt DL, Hirshberg B, Mosenzon O, Scirica BM, Umez-Eronini A, Im K, Stahre C, Buskila A, Iqbal N, Greenberger N, Lerch MM. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin. Diabetes Care. 2014 Sep;37(9):2435-41

 

276)       Cefalu WT, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, Raz I, Rosenstock J, Riddle MC. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. Diabetes Care. 2014 Sep;37(9):2647-59

 

277)Blumenfeld O1, Dichtiar R, Shohat T; Israel IDDM Registry Study Group (IIRSG) Trends in the incidence of type 1 diabetes among Jews and Arabs in Israel. Pediatr Diabetes. 2014 Sep;15(6):422-7. doi: 10.1111/pedi.12101. Epub 2013 Nov 27.

 

278)       Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenson O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; for the SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014 130(18):1579-88

 

 

279)       Zigmond E, Tayer-Shifman O, Lalazar G, Ben Ya'acov A, Weksler-Zangen S, Shasha D, Sklair-Levy M, Zolotarov L, Shalev Z, Kalman R, Ziv E, Raz I, Ilan Y. β-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model. J Inflamm Res. 2014 Oct 8;7:151-8

 

280)       Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, Del Prato S, Leroith D, Schernthaner G, van Gaal L, Raz I. Response to comment on home et Al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes care 2014;37:1499-1508. Diabetes Care. 2014 Nov;37(11):e247. doi: 10.2337/dc14-1790

 

281)Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM; for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care. 2015 38(4):696-705

 

282)Aharon-Hananel G, Jörns A, Lenzen S, Raz I, Weksler-Zangen S. Anti-diabetic Effect of Interleukin-1β Antibody Therapy through β-Cell Protection in the Cohen Diabetes-Sensitive Rat. Diabetes. 2015 64(5):1780-5

 

 

283)Pfützner A, Raz I, Bitton G, Klonoff D, Nagar R, Hermanns N, Haak T. Improved insulin absorption by means of standardized injection site modulation results in a safer and more efficient prandial insulin treatment.  A review of the existing clinical data. J Diabetes Sci Technol. 2015 Jan;9(1):116-22. doi: 10.1177/1932296814555400. Epub 2014 Oct 28

 

 

284)Leiter LA, Teoh H, Braunwald E, Mosenzon O, Cahn A, Kumar KM, Smahelova A, Hirshberg B, Stahre C, Frederich R, Bonnici F, Scirica BM, Bhatt DL, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. Diabetes Care. 2015 Jun;38(6):1145-53. doi: 10.2337/dc14-2868. Epub 2015 Mar 10

 

 

285)Khazrai YM, Buzzetti R, Del Prato S, Cahn A, Raz I, Pozzilli P. The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. J Diabetes Complications. 2015 May-Jun;29(4):599-606. doi: 10.1016/j.jdiacomp.2015.03.004. Epub 2015 Mar 11.

 

286)Raz I, Bitton G, Feldman D, Alon T, Pfutzner A, Tamborlane WV. Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control. J Diabetes Sci Technol. 2015 May;9(3):639-43. doi: 10.1177/1932296815578881. Epub 2015 Apr 16.

 

 

287)Cahn A, Livshits L, Srulevich A, Raz I, Yedgar S, Barshtein G. Diabetic foot disease is associated with reduced erythrocyte deformability. Int Wound J. 2015 May 28. doi: 10.1111/iwj.12466. [Epub ahead of print]

 

288)Cefalu WT, Bray GA, Home PD, Garvey WT, Klein S, Pi-Sunyer FX,  Hu FB,  Raz I, Van Gaal L, Wolfe BM, Ryan DH. Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 2015;38:1567–1582

 

289)Leibowitz G, Cahn A, Bhatt DL, Hirshberg B, Mosenzon O, Wei C, Jermendy G, Sheu WH, Sendon JL, Im K, Braunwald E, Scirica BM, Raz I. Impact of treatment with saxagliptin on glycaemic stability and beta cell function in the SAVOR-TIMI 53 study. Diab Obes Metab. 2015 17(5):487-94

 

290)Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewish BS, McGuire DK, Davidson J, Steg G, Bhatt DL. Response to letter regarding article: "Heart failure, saxagliptin and DM: Observations from the SAVOR-TIMI 53 randomized trial. Circulation 2015 132(6):e121-2

 

291)Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A, Hirshberg B, Cahn A, Stahre C, Strojek K, Bhatt DL, Raz I. Incidence of fractures in patients with type 2 diabets in the SAVOR-TIMI 53 trial. Diabetes Care 2015 38(11):2142-50

 

292)Dungan  KM, Raz I, Skrivanek Z, Seals W, Fahrbach JL. Achieving the composite endpoint of HbA1c<7.0%. No weight gain and no hypoglycaemia in the once weekly dulaglutide AWARD program. Diab Obes Metab 2015 Sep 12.doi: 10.1111/dom.12575. [Epub ahead of print] PMID: 26362460

 

 

 

293)Raz I, Cahn A, Mosenzon O, Scirica BM, Bhatt DL. Response to: Baseline differences in SAVOR trial – prespecified vs. post hoc analysis – a potential source of bias. Diab Obes Metab 2015 Sep 30. Doi: 10.1111/dom.12579 [Epub ahead of print] PMID: 26419822

 

294)Leiter L, Teoh H, Mosenzon O, Cahn A, Hirshberg B, Stahre CA, Hoekstra JB, Alvarsson M, Im K, Scirica BM, Bhatt DL, Raz I; SAVOR-TIMI 53 Steering Committee, Investigators. Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial. Diab Obes Metab. 20215 Oct 7.doi: 10.1111/dom.12582. [Epub ahead of print] PMID:26443993

 

 

 

295)Cahn A, Raz I, Kleinman Y, Balicer R, Hoshen M, Lieberman N, Brenig N, Del Prato S, Cefalu WT. clinical assessment of individualized glycemic goals in patients with type 2 diabetes: Formulation of an algorithm based on a survey among leading worldwide diabetologists. Diabetes Care 2015; DOI: 10.2337/dc15-0187 [Epub ahead of print]

 

296)Assayag-Asherie N, Sever D, Bogdani M, Johnson P, Weiss T, Ginzberg A, Perles S, Weiss L, Sebban LE, Turley EA, Okon E, Raz I, Naor D. Can CD44 Be a Mediator of Cell Destruction? The Challenge of Type 1 Diabetes. PLoS One. 2015 Dec 1;10(12):e0143589. doi: 10.1371/journal.pone.0143589. eCollection 2015

 

 

297)          Cavender MA, Scirica BM, Raz I, Steg PG, McGuire DK, Leiter LA, Hirshberg B, Davidson J, Cahn A, Mosenzon O, Im K, Braunwald E, Bhatt DL. Cardiovascular outcomes of patients in SAVOR-TIMI 53 by baseline Hemoglobin A1c. Am J Med  2015 Oct 30. pii: S0002-9343(15)01017-7 (5.003; 18/154)

 

298)Strojek K, Raz I, Jermendy G, Gitt AK, Liu R, Zhang Q, Jacober SJ, Milicevic Z. Factors associated with cardiovascular events in patients with type 2 diabetes and acute myocardial infarction. J Clin Endocrinol Metab. 2015 Nov 23:jc20151962. [Epub ahead of print] PMID:26595100

 

 

299)Raz I, Zary R, Ben Dayan E. Proposing a new design for self-monitoring blood glucose logs. Diab Metab Res Rev 2016 Jan;32(1):60-2

 

300)Masmiquel L, Leiter LA, Vidal J, Bain S, Petrie J, Franek E, Raz I, Comlekci A, Jacob S, van Gaal L, Baeres FM, Marso SP, Eriksson M; LEADER investigators. LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc Diabetol. 2016 Feb 10;15(1):29. doi: 10.1186/s12933-016-0341-5

301)Cernea S, Cahn A, Raz I. Saxagliptin for the treatment of diabetes - a focus on safety. Expert Opin Drug Saf. 2016 Feb 27. [Epub ahead of print

 

302)Raz I, Cahn A. Heart failure: SGLT2 inhibitors and heart failure - clinical implications. Nat Rev Cardiol. 2016 Mar 10. doi: 10.1038/nrcardio.2016.35. [Epub ahead of print]

 

303)Cahn A, Cernea S, Raz I. Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. Rev Endocr Metab Disord. 2016 Apr 23. [Epub ahead of print] Review. PMID:27106831

 

304)Landau Z, Raz I, Wainstein J, Bar-Dayan Y, Cahn A. the role of insulin pump therapy in type 2 diabetes mellitus. Diabetes Metab Res Rev. 2016 May 18. doi: 10.1002/dmrr.2822. [Epub ahead of print] Review.PMID:27189155

 

305)Ish-Shalom M, Wainstein J, Raz I, Mosenzon O. Improvement in glucose control in difficult-to-control patients with diabetes using a novel flash glucose monitoring device. J Diabetes Sci Technol. 2016 June 8.pii: 1932296816653412. [Epub ahead of print]

 

 

306)Cahn A, Raz I, Mosenzon O, Leibowitz G, Yanuv I, Rozenberg A, Iqbal N, Hirshberg B, Sjostrand M, Stahre C, Im K, Kanevsky E, Scirica BM, Bhatt DL, Braunwald E.  Predisposing factors for any and major hypoglycemia with saxagliptin versus placebo and overall: Analysis from the SAVOR-TIMI 53 Trial. Diabetes Care. 2016 May 23.pii: dc152763. [Epub ahead of print]

 

307)Schernthaner G, Cahn A, Raz I. Is the use of DPP-4 inhibitors associated with an increased risk for heart failure? Lessons from EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes Care. 2016 Aug;39 Suppl 2:S210-8. doi: 10.2337/dcS15-3009. No abstract available.PMID:27440835

 

 

308)Mosenzon O, Pollack R, Raz I. Treatment of type 2 diabetes: from "guidelines" to "position statements" and back: Recommendations of the Israel National Diabetes Council. Diabetes Care. 2016 Aug;39 Suppl 2:S146-53. doi: 10.2337/dcS15-3003.PMID:27440827

 

309)Raz I, Cefalu WT, Ilkova H, Del Prato S. Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Diabetes Care. 2016 Aug;39 Suppl 2:S113-4. doi: 10.2337/dcS15-3030. No abstract available. PMID:27440822

 

310)Kochba E, Levin Y, Raz I, Cahn A. Improved insulin pharmacokinetics using a novel microneedle device for intradermal delivery in patients with type 2 diabetes. Diabetes Technol Ther. 2016 Sep;18(9):525-31. doi:10.1089/dia.2016.0156

 

311)Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE. Update and next steps for real-world translation of interventions for type 2 diabetes prevention: Reflections from a Diabetes Care editors' expert forum. Diabetes Care. 2016 Jul;39(7):1186-201. doi: 10.2337/dc16-0873

 

312)Tkáč I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care. 2016 Sep 22. pii: dc151707. [Epub ahead of print]

 

313)Scirica BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im K, Mosenzon O, Udell JA, Hirshberg B, Pollack PS, Steg PG, Jarolim P, Morrow DA.Prognostic Implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: A secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016 Sep 28. doi: 10.1001/jamacardio.2016.3030. [Epub ahead of print]

 

314)Kogot-Levin A, Saada A, Leibowitz G, Soiferman D, Douiev L, Raz I, Weksler-Zangen S. Upregulation of mitochondrial content in cytochrome c oxidasedeficient fibroblasts. PLoS One. 2016 Oct 25;11(10):e0165417. doi: 10.1371/journal.pone.0165417.

 

315)Mosenzon O, Leibowitz G, Bhatt DL, Cahn A, Hirshberg B, Wei C, Im K, Rozenberg A, Yanuv I, Stahre C, Ray KK, Iqbal N, Braunwald E, Scirica BM, Raz I Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2016 Oct 17. pii: dc160621. [Epub ahead of print]

 

316)Ish-Shalom M, Wainstein J, Raz I, Mosenzon O.  Improvement in glucose control in difficult-to-control patients with diabetes using a novel flash glucose monitoring device. J Diabetes Sci Technol. 2016 Nov 1;10(6):1412-1413. No abstract available. PMID 27277660

 

 

317)Cahn A, Cernea S, Raz I. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Nov 18:1-11. [Epub ahead of print] PMID:27809608

 

318)Raz I, Cahn A. Comment on Shahraz et al. Do patient characteristics impact decisions by clinicians on Hemoglobin A1c targets? Diabetes Care.  2016 Dec;39(12):e227. No abstract available.

 

319)Cahn A, Roitman E, Aharon-Hananel G, Raz I. Continuous subcutaneous insulin infusion-an opportunity for better care but not a "magic pill". Endocrine. 2016 Dec 30. doi: 10.1007/s12020-016-1217-x. [Epub ahead of print] No abstract available.

 

320)Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE. Response to comment on Cefalu et al. Update and next steps for real-world translation of interventions for type 2 diabetes prevention: reflections from a Diabetes Care editors expert forum. Diabetes Care. 2017 Feb;40(2):e23-e24. doi:10.2337/dci16-0036. PMID:28108540

 

321)Cahn A, Mosenzon O, Bhatt DL, Leibowitz G, Yanuv I, Rozenberg A, Iqbal N, Hirshberg B, Stahre C, Im K, Kanevsky E, Raz I. Hypoglycemia manifestations and recurrent events: lessons from the SAVOR-TIMI 53 outcome study. Diabetes Obes Metab. 2017 Feb 9. Doi: 10.1111/dom.12903. PMID: 28181728

 

322)Lalazar G, Zigmond E, Weksler-Zangen S, Ben Ya'acov A, Sklair Levy M, Hemed N, Raz I, Ilan Y. Oral administration of β-Glucosylceramide for the treatment of insulin resistance and nonalcoholic steatohepatitis: Results of a double-blind, placebo-controlled trial. J Med Food. 2017 Apr 7. doi: 10.1089/jmf.2016.3753. [Epub ahead of print]PMID:28387617

 

323)Cernea S, Cahn A, Raz I. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Rev Clin Pharmacol. 2017 Mar 6:1-13. doi: 10.1080/17512433.2017.1300059. [Epub ahead of print] PMID:28276774

 

324)Briggs AH, Bhatt DL, Scirica BM, Raz I, Johnston KM, Szabo SM, Bergenheim K, Mukherjee J, Hirshberg B, Mosenzon O. Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes recorded in patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes Res Clin Pract. 2017 Jan 23;130:24-33. doi: 10.1016/j.diabres.2016.12.019. [Epub ahead of print] PMID:28554140

 

325)Spivak H, Sakran N, Dicker D, Rubin M, Raz I, Shohat T, Blumenfeld O. Different effects of bariatric surgical procedures on dyslipidemia: a registry-based analysis. Surg Obes Relat Dis. 2017 Mar 23. pii: S1550-7289(17)30144-2. doi: 10.1016/j.soard.2017.03.013. [Epub ahead of print]PMID:28456511

 

326)Peled A, Gordon B, Twig G, Mendlovic J, Derazne E, Lisnyansky M, Raz I, Afek A. Immigration to Israel during childhood is associated with diabetes at adolescence: a study of 2.7 million adolescents. Diabetologia. 2017 Aug 19. doi: 10.1007/s00125-017-4399-8. [Epub ahead of print]PMID:28821907

 

 

327)Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.

 

328)Jakubowicz D, Wainstein J, Landau Z, Raz I, Ahren B, Chapnik N, Ganz T, Menaged M, Barnea M, Bar-Dayan Y, Froy O. Influences of breakfast on clock gene expression and postprandial glycemia in healthy individuals and individuals with diabetes: A randomized clinical trial. Diabetes Care. 2017 Nov;40(11):1573-1579. doi: 10.2337/dc16-2753. Epub 2017 Aug 22.

 

329)Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

 

330)Cahn A, Akirov A, Raz I. Digital therapy in diabetes. J Diabetes. 2017 Jan;10(1):10-17. . doi: 10.1111/1753-0407.12606. Epub 2017 Nov 6

331)Bergmark BA, Bhatt DL, Braunwald E, Morrow DA, Steg PG, Gurmu Y, Cahn A, Mosenzon O, Raz I, Bohula E, Scirica BM. Risk assessment in patients with diabetes with the TIMI risk score for atherothrombotic disease. Diabetes Care. 2017 Dec 1. pii: dc171736. doi: 10.2337/dc17-1736. [Epub ahead of print] PMID: 29196298

 

332)Scirica BM, Mosenzon O, Bhatt DL, Udell JA, Steg PG, McGuire DK, Im K, Kanevsky E, Stahre C, Sjöstrand M, Raz I, Braunwald E.  Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: Observations from the SAVOR-TIMI 53 trial.  JAMA Cardiol. 2017 Dec 6. doi: 10.1001/jamacardio.2017.4228. [Epub ahead of print]

 

333)Spivak H, Munz Y, Rubin M, Raz I, Shohat T, Blumenfeld O.  Omega-loop gastric bypass is more effective for weight loss but negatively impacts liver enzymes: A registry-based comprehensive first-year analysis. Surg Obes Relat Dis. 2017 Nov 9. pii: S1550-7289(17)31040-7. doi: 10.1016/j.soard.2017.11.006. [Epub ahead of print] PMID: 29217131

 

334)Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC.  Cardiovascular outcomes trials in type 2 diabetes: Where do we go from here? Reflections from a Diabetes Care editors' expert forum. Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.

 

335)Alvarez-Guisasola F, Cebrián-Cuenca AM, Cos X, Ruiz-Quintero M, Millaruelo JM, Cahn A, Raz I, Orozco-Beltrán D; Spanish Society of Family Medicine Diabetes Group.  Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real-life clinical practice. Diabetes Metab Res Rev. 2017 Dec 22. doi: 10.1002/dmrr.2976. [Epub ahead of print]

 

 

336)Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, Bhatt DL, Leiter LA, McGuire DK, Wilding J, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS, Wiviott SD. Declare-Timi 58: Participants' baseline characteristics. Diabetes Obes Metab. 2018 Jan 11. doi: 10.1111/dom.13217. [Epub ahead of print] PMID: 29322605

 

337)Bergmark BA, Scirica BM, Steg PG, Fanola CL, Gurmu Y, Mosenzon O, Cahn A, Raz I, Bhatt DL; SAVOR-TIMI 53 Investigators. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. Eur Heart J. 2018 Jan 31. doi: 10.1093/eurheartj/ehx809. [Epub ahead of print] PMID:29394350

 

 

338)Sakran N, Sherf-Dagan S, Blumenfeld O, Romano-Zelekha O, Raziel A, Keren D, Raz I, Hershko D, Gralnek IM, Shohat T, Goitein D. Incidence and risk factors for mortality following bariatric surgery: a nationwide registry study. Obes Surg. 2018 Apr 7. doi: 10.1007/s11695-018-3212-1. [Epub ahead of print] PMID:29627947

 

339)Ceriello A, Gavin JR 3rd, Boulton AJM, Blickstead R, McGill M, Raz I, Sadikot S, Wood DA, Cos X, Khunti K, Kalra S, Das AK, López CE; Berlin Declaration Steering Group. The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help? Diabetes Res Clin Pract. 2018 Mar 27. pii: S0168-8227(18)30465-0. doi: 10.1016/j.diabres.2018.03.037. [Epub ahead of print] PMID:29596943

 

340)Sakran N, Sherf-Dagan S, Blumenfeld O, Romano-Zelekha O, Raziel A, Keren D, Raz I, Hershko D, Gralnek IM, Shohat T, Goitein D. Correction to: Incidence and Risk Factors for Mortality Following Bariatric Surgery: a Nationwide Registry Study. Obes Surg. 2018 Apr 25. doi: 10.1007/s11695-018-3274-0. [Epub ahead of print] PMID:29744715

 

341)Khunti K, Gavin JR 3rd, Boulton AJM, Blickstead R, McGill M, Ceriello A, Raz I, Sadikot S, Wood DA, Cos X, Kalra S, Das AK, Espinosa López C; Berlin Declaration Steering Group. The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important? Prim Care Diabetes. 2018 May 8. pii: S1751-9918(18)30076-7. doi: 10.1016/j.pcd.2018.04.003. [Epub ahead of print] Review. PMID: 29752222

 

342)    Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018 Jun;200:83-89. doi: 10.1016/j.ahj.2018.01.012. Epub 2018 Feb 7. PMID:29898853

 

 

343)Shehadeh N, Raz I, Nakhleh A. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease. Cardiovasc Diabetol. 2018 Aug 22;17(1):117. doi: 10.1186/s12933-018-0760-6. PMID:30134893

 

344)Delgado-Hurtado JJ, Cahn A, Raz I, Comi RJ. Comparison of hba1c goals proposed by an algorithm to those set by different members of healthcare teams within the dartmouth hitchcock health system. Endocr Pract. 2018 Aug;24(8):705-709. doi: 10.4158/EP-2018-0102.PMID:30183396

 

 

345)Bergman M, Manco M, Sesti G, Dankner R, Pareek M, Jagannathan R, Chetrit A, Abdul-Ghani M, Buysschaert M, Olsen MH, Nilsson PM, Medina JL, Roth J, Groop L, Del Prato S, Raz I, Ceriello A. Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 155 mg/dl (8.6 mmol/L). Diabetes Res Clin Pract. 2018 Sep 28;146:18-33. doi: 10.1016/j.diabres.2018.09.017. [Epub ahead of print] Review. PMID:30273707

 

 

346)Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812389. [Epub ahead of print] PMID:30415602

 

347)Cahn A, Altaras T, Agami T, Liran O, Touaty CE, Drahy M, Pollack R, Raz I, Chodick G, Zucker I. Validity of Diagnostic Codes and Estimation of Prevalence of Diabetic Foot Ulcers using a Large Electronic Medical Record Database. Diabetes Metab Res Rev. 2018 Oct 30:e3094. doi: 10.1002/dmrr.3094. [Epub ahead of print] PMID:30378240

 

348)Gutierrez JA, Scirica BM, Bonaca MP, Steg PG, Mosenzon O, Hirshberg B, Im K, Raz I, Braunwald E, Bhatt DL. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients with Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). Am J Cardiol. 2018 Sep 26. pii: S0002-9149(18)31835-6. doi: 10.1016/j.amjcard.2018.09.014. [Epub ahead of print] PMID:30366601

 

349)Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL,. Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. The Lancet (Published Online November 10, 2018http://dx.doi.org/10.1016/S0140-6736(18)32590-X) (953.254)

 

350)Karpati T, Leventer-Roberts M, Feldman B, Cohen-Stavi C, Raz I, Balicer R. Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes. PLoS One. 2018 Nov 14;13(11):e0207096. doi: 10.1371/journal.pone.0207096. eCollection 2018. PMID: 30427908

 

 

351)Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation. 2018 Dec 18;138(25):2908-2918. doi: 10.1161/CIRCULATIONAHA.118.036418. PMID: 30566006

 

352)Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. Circulation. 2019 Feb 21. doi: 10.1161/CIRCULATIONAHA.118.038868. [Epub ahead of print. PMID: 30786725

 

353)Aharon-Hananel G, Raz I. An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. Expert Opin Pharmacother. 2019 Mar 5:1-10. doi: 10.1080/14656566.2019.1583210. [Epub ahead of print] PMID: 30835599

 

 

354)Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.040130. [Epub ahead of print] PMID:30882238

 

355)Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial. Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.039996. [Epub ahead of print] PMID:30882239

356)Bitton G, Rom V, Hadelsberg U, Raz I, Cengiz E, Weinzimer S, Tamborlane WV. Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics. J Diabetes Sci Technol. 2019 May 8:1932296819842151. doi: 10.1177/1932296819842151. [Epub ahead of print] PMID:31067999

 

357)Yaron M, Roitman E, Aharon-Hananel G, Landau Z, Ganz T, Yanuv I, Rozenberg A, Karp M, Ish-Shalom M, Singer J, Wainstein J, Raz I. Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Diabetes Care. 2019 Apr 29. pii: dc180166. doi: 10.2337/dc18-0166. [Epub ahead of print] PMID:31036546

 

 

358)Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BM. Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. Clin Chem. 2019 Apr 15. pii: clinchem.2018.298489. doi: 10.1373/clinchem.2018.298489. [Epub ahead of print]

 

359)Wiviott SD, Raz I, Sabatine MS.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply. N Engl J Med. 2019 May 9;380(19):1881-1882. doi: 10.1056/NEJMc1902837. No abstract available. PMID:31067395

 

360)Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR. Response by Mann et al. to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial". Circulation. 2019 May 28;139(22):e1017-e1018.doi:10.1161/CIRCULATIONAHA.119.040419. Epub 2019 May 28. No abstract available.

 

361)Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019 Jun 10. pii: S2213-8587(19)30180-9. doi: 10.1016/S2213-8587(19)30180-9. [Epub ahead of print]PMID:31196815

 

362)      Bergmark B, Bhatt D, McGuire D, Cahn A, Mosenzon O, Steg PG, Im KA, Kanevsky E, Gurmu Y, Raz I, Braunwald E, Scirica B. Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction - Observations from the SAVOR-TIMI 53 Trial. Circulation. 2019 Jul 31. doi: 10.1161/CIRCULATIONAHA.119.040144. [Epub ahead of print] PMID:31362530

 

363)Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MS. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus. Circulation. 2019 Aug 31. doi:10.1161/CIRCULATIONAHA.119.042685. [Epub ahead of print] No abstract available. PMID:31474116

 

364)Cernea S, Raz I. Insulin Therapy: Future Perspectives. Am J Ther. 2019 Sep 12. doi: 10.1097/MJT.0000000000001076. [Epub ahead of print]

 

365)Bendor CD, Bardugo A, Zucker I, Cukierman-Yaffe T, Lutski M, Derazne E, Shohat T, Mosenzon O, Tzur D, Sapir A, Pinhas-Hamiel O, Kibbey RG, Raz I, Afek A, Gerstein HC, Tirosh A, Twig G. Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood. Diabetes Care. 2019 Nov 6. pii: dc191562. doi: 10.2337/dc19-1562. [Epub ahead of print] PMID: 31694859

 

366)Jakubowicz D, Landau Z, Tsameret S, Wainstein J, Raz I, Ahren B, Chapnik N, Barnea M, Ganz T, Menaged M, Mor N, Bar-Dayan Y, Froy O. Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. Diabetes Care. 2019 Dec;42(12):2171-2180. doi: 10.2337/dc19-1142. Epub 2019 Sep 23. PMID: 31548244

 

 

367)     Raz I, Cernea S, Cahn A. SGLT2 inhibitors for primary prevention of cardiovascular events. J Diabetes. 2020 Jan;12(1):5-7. doi: 10.1111/1753-0407.13004. Epub 2019 Nov 21.

 

 

368)Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study Diabetes Care. 2019 Dec 16. pii: dc191476. doi: 10.2337/dc19-1476. [Epub ahead of print] PMID:31843945

 

369)Jakubowicz D, Landau Z, Tsameret S, Wainstein J, Raz I, Ahren B, Chapnik N, Barnea M, Ganz T, Menaged M, Mor N, Bar-Dayan Y, Froy O.  Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. Diabetes Care. 2019 Dec;42(12):2171-2180. doi: 10.2337/dc19-1142. Epub 2019 Sep 23.PMID:31548244

 

370)Zelniker TA, Bonaca MP, Furtado R, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial. Circulation. 2020 Jan 27. doi: 10.1161/CIRCULATIONAHA.119.044183. [Epub ahead of print] PMID:31983236

 

371)Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O; LEADER Trial Investigators. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clin J Am Soc Nephrol. 2020 Mar 4. pii: CJN.11881019. doi: 10.2215/CJN.11881019. [Epub ahead of print] PMID: 32132141

 

 

372)   Bajaj HSC, Raz Ico-PI, Mosenzon OC, Murphy SAC, Rozenberg AC, Yanuv IC, Bhatt DLC, Leiter LAC, McGuire DKC, Wilding JPHC, Gause-Nilsson IAMC, Sabatine MSC, Wiviott SDco-PI, Cahn AC.  Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: analyses from the DECLARE-TIMI 58 trial. Diabetes Obes Metab. 2020 Feb 23. doi: 10.1111/dom.14011. [Epub ahead of print] 5.980

 

371.  Khanh TQ, Hao PN, Roitman E, Raz I, Marganitt B, Cahn A. Digital Diabetes Care System Observations from a Pilot Evaluation Study in Vietnam. Int J Environ Res Public Health. 2020 Feb 3;17(3). pii: E937. doi: 10.3390/ijerph17030937.

 

372.   Cahn A, Cernea S, Raz I. The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease? Int J Environ Res Public Health. 2020 Feb 3;17(3). pii: E937. doi: 10.3390/ijerph17030937. PMID: 32028707

 

373.   Cahn A, Shoshan A, Sagiv T, Yesharim R, Goshen R, Shalev V, Raz I. Prediction of progression from pre-diabetes to diabetes: Development and validation of a machine learning model. Diabetes Metab Res Rev. 2020 Feb;36(2):e3252. doi: 10.1002/dmrr.3252. Epub 2020 Jan 14. PMID: 31943669

 

374.   
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.

Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, De Mendonca Furtado RH, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MS.Circulation. 2020 Aug 25;142(8):734-747. doi: 10.1161/CIRCULATIONAHA.119.044775. Epub 2020 Aug 3.PMID: 32795086 Clinical Trial.

 

375. NAFLD in type 2 diabetes mellitus: Still many challenging questions.

Cernea S, Raz I.Diabetes Metab Res Rev. 2021 Feb;37(2):e3386. doi: 10.1002/dmrr.3386. Epub 2020 Aug 18.PMID: 32677717 Review.

 

376. Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial.

Mosenzon O, Bain SC, Heerspink HJL, Idorn T, Mann JFE, Persson F, Pratley RE, Rasmussen S, Rossing P, von Scholten BJ, Raz I; LEADER Trial Investigators.Diabetes Obes Metab. 2020 Nov;22(11):2077-2088. doi: 10.1111/dom.14126. Epub 2020 Aug 7.PMID: 32618386 Free PMC article. Clinical Trial.

 

377. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel.

Consoli A, Czupryniak L, Duarte R, Jermendy G, Kautzky-Willer A, Mathieu C, Melo M, Mosenzon O, Nobels F, Papanas N, Roman G, Schnell O, Sotiropoulos A, Stehouwer CDA, Tack CJ, Woo V, Fadini GP, Raz I.Diabetes Obes Metab. 2020 Oct;22(10):1705-1713. doi: 10.1111/dom.14102. Epub 2020 Jul 5.PMID: 32476244 Review.

 

378. Adolescent Obesity and Early-Onset Type 2 Diabetes.

Twig G, Zucker I, Afek A, Cukierman-Yaffe T, Bendor CD, Derazne E, Lutski M, Shohat T, Mosenzon O, Tzur D, Pinhas-Hamiel O, Tiosano S, Raz I, Gerstein HC, Tirosh A.Diabetes Care. 2020 Jul;43(7):1487-1495. doi: 10.2337/dc19-1988. Epub 2020 Apr 22.PMID: 32321731

 

379. Sodium glucose co-transporter 2 inhibitors in heart failure therapy.

Çavuşoğlu Y, Altay H, Cahn A, Celik A, Demir S, Kılıçaslan B, Nalbantgil S, Raz I, Temizhan A, Yıldırımtürk Ö, Yılmaz MB.Turk Kardiyol Dern Ars. 2020 Apr;48(3):330-354. doi: 10.5543/tkda.2020.74332.PMID: 32281958 Free article. English. No abstract available.

 

380. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study.

Cahn A, Raz I, Bonaca M, Mosenzon O, Murphy SA, Yanuv I, Rozenberg A, Wilding JPH, Bhatt DL, McGuire DK, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Jermendy G, Hadjadj S, Langkilde AM, Sabatine MS, Wiviott SD, Leiter LA.Diabetes Obes Metab. 2020 Aug;22(8):1357-1368. doi: 10.1111/dom.14041. Epub 2020 Apr 27.PMID: 32239659 Clinical Trial.

 

 

 

381. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.

Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O; LEADER Trial Investigators.Clin J Am Soc Nephrol. 2020 Apr 7;15(4):465-473. doi: 10.2215/CJN.11881019. Epub 2020 Mar 4.PMID: 32132141 Free PMC article. Clinical Trial.

 

382. Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.

Bajaj HS, Raz I, Mosenzon O, Murphy SA, Rozenberg A, Yanuv I, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Sabatine MS, Wiviott SD, Cahn A.Diabetes Obes Metab. 2020 Jul;22(7):1122-1131. doi: 10.1111/dom.14011. Epub 2020 Mar 12.PMID: 32090404 Clinical Trial.

 

383. Digital Diabetes Care System Observations from a Pilot Evaluation Study in Vietnam.

Khanh TQ, Hao PN, Roitman E, Raz I, Marganitt B, Cahn A.Int J Environ Res Public Health. 2020 Feb 3;17(3):937. doi: 10.3390/ijerph17030937.PMID: 32028707 Free PMC article.

 

384. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.

Marston NA, Patel PN, Kamanu FK, Nordio F, Melloni GM, Roselli C, Gurmu Y, Weng LC, Bonaca MP, Giugliano RP, Scirica BM, O'Donoghue ML, Cannon CP, Anderson CD, Bhatt DL, Gabriel Steg P, Cohen M, Storey RF, Sever P, Keech AC, Raz I, Mosenzon O, Antman EM, Braunwald E, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CT.Circulation. 2021 Feb 2;143(5):470-478. doi: 10.1161/CIRCULATIONAHA.120.051927. Epub 2020 Nov 13.PMID: 33185476

 

385. Five years into the Israeli National Diabetes Program - are we on the right track?

Tamir O, Afek A, Shani M, Cahn A, Raz I.Diabetes Metab Res Rev. 2021 Sep;37(6):e3421. doi: 10.1002/dmrr.3421. Epub 2020 Nov 25.PMID: 33175454 Review.

 

386. Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents.

Fishman B, Grossman E, Zucker I, Orr O, Lutski M, Bardugo A, Bendor CD, Leiba Y, Cukierman-Yaffe T, Derazne E, Mosenzon O, Tzur D, Beer Z, Pinhas-Hamiel O, Fishman T, Afek A, Tirosh A, Raz I, Gerstein HC, Twig G.Diabetes Care. 2021 Jan;44(1):e6-e8. doi: 10.2337/dc20-1752. Epub 2020 Nov 4.PMID: 33148634 No abstract available.

 

387. The relationship between inpatient hyperglycaemia and mortality is modified by baseline glycaemic status.

Rayyan-Assi H, Feldman B, Leventer-Roberts M, Akriv A, Raz I.Diabetes Metab Res Rev. 2021 Sep;37(6):e3420. doi: 10.1002/dmrr.3420. Epub 2020 Dec 7.PMID: 33137237

 

388. Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. Bardugo A, Bendor CD, Zucker I, Lutski M, Cukierman-Yaffe T, Derazne E, Mosenzon O, Tzur D, Beer Z, Pinhas-Hamiel O, Ben-Ami M, Fishman B, Ben-Ami Shor D, Raz I, Afek A, Gerstein HC, Häring HU, Tirosh A, Levi Z, Twig G.J Clin Endocrinol Metab. 2021 Jan 1;106(1):e34-e44. doi: 10.1210/clinem/dgaa753.PMID: 33075820

 

389. Adolescent BMI and early-onset type 2 diabetes among Ethiopian immigrants and their descendants: a nationwide study.

Simchoni M, Hamiel U, Pinhas-Hamiel O, Zucker I, Cukierman-Yaffe T, Lutski M, Derazne E, Beer Z, Behar D, Keinan-Boker L, Mosenzon O, Tzur D, Afek A, Tirosh A, Raz I, Twig G.Cardiovasc Diabetol. 2020 Oct 6;19(1):168. doi: 10.1186/s12933-020-01143-z.PMID: 33023586 Free PMC article.

 

390. Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial".

Zelniker TA, Raz I, Sabatine MS, Wiviott SD.Circulation. 2020 Sep 8;142(10):e129-e130. doi: 10.1161/CIRCULATIONAHA.120.049841. Epub 2020 Sep 8.PMID: 32897752 No abstract available.

 

391. Haemoglobin A1c is a predictor of COVID-19 severity in patients with diabetes.

Merzon E, Green I, Shpigelman M, Vinker S, Raz I, Golan-Cohen A, Eldor R.Diabetes Metab Res Rev. 2021 Jul;37(5):e3398. doi: 10.1002/dmrr.3398. Epub 2020 Sep 23.PMID: 32852883 Free PMC article.

 

392. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.

Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Wilding JPH, Leiter LA, Bhatt DL, McGuire DK, Litwak L, Kooy A, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Raz I.Diabetes Obes Metab. 2021 Jan;23(1):29-38. doi: 10.1111/dom.14179. Epub 2020 Sep 22.PMID: 32844557 Clinical Trial.

 

393. Tackling obesity during the COVID-19 pandemic.

Akirov A, Cahn A, Del Prato S, Home P, Van Gaal L, Chan J, Ning G, Raz I.Diabetes Metab Res Rev. 2021 Mar;37(3):e3393. doi: 10.1002/dmrr.3393. Epub 2020 Aug 29.PMID: 32797666 Free PMC article. No abstract available.

 

394. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin.

Fontes-Carvalho R, Santos-Ferreira D, Raz I, Marx N, Ruschitzka F, Cosentino F.Eur J Prev Cardiol. 2021 Feb 28:zwab034. doi: 10.1093/eurjpc/zwab034. Online ahead of print.PMID: 33659986

 

395. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.

396. Cahn A, Raz I, Leiter LA, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Wiviott SD.Diabetes Care. 2021 May;44(5):1159-1167. doi: 10.2337/dc20-2492. Epub 2021 Mar 2.PMID: 33653824 Clinical Trial.

 

397. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.

O'Donoghue ML, Kato ET, Mosenzon O, Murphy SA, Cahn A, Herrera M, Tankova T, Šmahelová A, Merlini P, Gause-Nilsson I, Langkilde AM, McGuire DK, Wilding JPH, Leiter LA, Bhatt DL, Raz I, Sabatine MS, Wiviott SD.Diabetologia. 2021 Jun;64(6):1226-1234. doi: 10.1007/s00125-021-05399-2. Epub 2021 Feb 20.PMID: 33611623

 

398. Reply to the letter of Draves et al. In response to the article: "Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization" (Kesavadev et al.)".

Kesavadev J, Misra A, Saboo B, Aravind SR, Hussain A, Czupryniak L, Raz I.Diabetes Metab Syndr. 2021 Jan-Feb;15(1):466. doi: 10.1016/j.dsx.2021.02.006. Epub 2021 Feb 7.PMID: 33589363 No abstract available.

 

399. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.

Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann JFE, Pratley R, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Rossing P; LEADER Trial Investigators.Diabetes Care. 2021 Apr;44(4):1020-1026. doi: 10.2337/dc20-1622. Epub 2021 Jan 27.PMID: 33504496 Free PMC article. Clinical Trial.

 

400. Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization.

Kesavadev J, Misra A, Saboo B, Aravind SR, Hussain A, Czupryniak L, Raz I.Diabetes Metab Syndr. 2021 Jan-Feb;15(1):221-227. doi: 10.1016/j.dsx.2020.12.032. Epub 2021 Jan 2.PMID: 33450531 Free PMC article. Review.

 

401. Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents.

Tsur AM, Hershkovich S, Zucker I, Lutski M, Pinhas-Hamiel O, Vivante A, Fischman M, Amir O, Rotchild J, Gerstein HC, Cukierman-Yaffe T, Friedensohn L, Mosenzon O, Derazne E, Tzur D, Tirosh A, Afek A, Raz I, Twig G.J Clin Endocrinol Metab. 2021 Mar 25;106(4):978-987. doi: 10.1210/clinem/dgaa988.PMID: 33449080

 

402. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease.

Marston NA, Melloni GEM, Gurmu Y, Bonaca MP, Kamanu FK, Roselli C, Lee C, Cavallari I, Giugliano RP, Scirica BM, Bhatt DL, Steg PG, Cohen M, Storey RF, Keech AC, Raz I, Mosenzon O, Braunwald E, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT.Circ Genom Precis Med. 2021 Feb;14(1):e003006. doi: 10.1161/CIRCGEN.120.003006. Epub 2021 Jan 12.PMID: 33434447

 

403. Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa.

Giorgino F, Bhana S, Czupryniak L, Dagdelen S, Galstyan GR, Janež A, Lalić N, Nouri N, Rahelić D, Stoian AP, Raz I.Diabetes Res Clin Pract. 2021 Feb;172:108617. doi: 10.1016/j.diabres.2020.108617. Epub 2020 Dec 10.PMID: 33310175 Free PMC article. Review.

 

404. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58.

Zelniker TA, Morrow DA, Mosenzon O, Goodrich EL, Jarolim P, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding J, Bode C, Lewis BS, Gause-Nilsson I, Langkilde AM, Fredriksson M, Raz I, Sabatine MS, Wiviott SD.Eur J Heart Fail. 2021 Jun;23(6):1026-1036. doi: 10.1002/ejhf.2073. Epub 2020 Dec 29.PMID: 33269486 Clinical Trial.

 

 

 

405. Asthma in Youth and Early-Onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents.

Shapiro M, Arbel C, Zucker I, Balmor GR, Lutski M, Derazne E, Beer Z, Pinhas-Hamiel O, Mosenzon O, Tzur D, Afek A, Tirosh A, Cukierman-Yaffe T, Gerstein HC, Rosenberg V, Chodik G, Raz I, Twig G.J Clin Endocrinol Metab. 2021 Jul 22:dgab542. doi: 10.1210/clinem/dgab542. Online ahead of print.PMID: 34291806

 

406. Serum from type 2 diabetes patients consuming a three-meal diet resets circadian rhythms in cultured hepatocytes.

Tsameret S, Jakubowicz D, Landau Z, Wainstein J, Ganz T, Raz I, Chapnik N, Froy O.Diabetes Res Clin Pract. 2021 Aug;178:108941. doi: 10.1016/j.diabres.2021.108941. Epub 2021 Jul 8.PMID: 34245798

 

407. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.

Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I.Diabetes Care. 2021 Aug;44(8):1805-1815. doi: 10.2337/dc21-0076. Epub 2021 Jul 7.PMID: 34233928 Free PMC article.

 

408. Machine learning based study of longitudinal HbA1c trends and their association with all-cause mortality: Analyses from a National Diabetes Registry.

Cahn A, Zuker I, Eilenberg R, Uziel M, Tsadok MA, Raz I, Lutski M.Diabetes Metab Res Rev. 2021 Jul 7:e3485. doi: 10.1002/dmrr.3485. Online ahead of print.PMID: 34233382

 

409. Effect of a primary-care-team focused diabetes educational program project on diabetes care quality indicators in a large health maintenance organization.

Eldor R, Merzon E, Shpigelman M, Tamir O, Vinker S, Raz I, Merhasin I, Wald D, Golan-Cohen A.Diabetes Res Clin Pract. 2021 Jul;177:108896. doi: 10.1016/j.diabres.2021.108896. Epub 2021 Jun 5.PMID: 34098056

 

410. Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood.

Bardugo A, Derazne E, Zucker I, Bendor CD, Puris G, Lutski M, Pinhas-Hamiel O, Cukierman-Yaffe T, Mosenzon O, Schechter M, Tzur D, Afek A, Tirosh A, Gerstein HC, Raz I, Twig G.J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3426-e3435. doi: 10.1210/clinem/dgab382.PMID: 34050759

 

411. From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.

Mosenzon O, Del Prato S, Schechter M, Leiter LA, Ceriello A, DeFronzo RA, Raz I.Cardiovasc Diabetol. 2021 Apr 28;20(1):92. doi: 10.1186/s12933-021-01281-y.PMID: 33910583 Free PMC article. Review.

 

412. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD.JAMA Cardiol. 2021 Jul 1;6(7):801-810. doi: 10.1001/jamacardio.2021.0660.PMID: 33851953

 

413. Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial.

Cavallari I, Bhatt DL, Steg PG, Leiter LA, McGuire DK, Mosenzon O, Im K, Raz I, Braunwald E, Scirica BM.J Am Coll Cardiol. 2021 Apr 13;77(14):1837-1840. doi: 10.1016/j.jacc.2021.02.030.PMID: 33832610 No abstract available.

 

414. Preinfection glycaemic control and disease severity among patients with type 2 diabetes and COVID-19: A retrospective, cohort study.

Hayek S, Ben-Shlomo Y, Balicer R, Byrne K, Katz M, Kepten E, Raz I, Roitman E, Zychma M, Barda N.Diabetes Obes Metab. 2021 Aug;23(8):1995-2000. doi: 10.1111/dom.14393. Epub 2021 Apr 16.PMID: 33822446 Free PMC article. No abstract available.

 

415. THE CHALLENGE OF HEALTHY AGING WITH DIABETES: THE ISRAELI NATIONAL DIABETES COUNCIL GUIDELINES FOR TREATING OLDER PEOPLE].

Azmon M, Cukierman-Yaffe T, Lahad A, Ben Israel J, Levin-Zamir D, Wainstein J, Mosenzon O, Raz I.Harefuah. 2021 Oct;160(10):693-697.PMID: 34689441 Hebrew.

 

 

416. [NATIONAL DIABETES PROGRAM IN ISRAEL AND IN SELECTED COUNTRIES - CURRENT STATE AND FUTURE TRENDS].

Tamir O, Skudowitz M, Raz I.Harefuah. 2021 Oct;160(10):685-692.PMID: 34689440 Review. Hebrew.

 

417. [COMPARISON OF A RECOMMENDATION FOR A DESIRABLE HBA1C VALUE BY INTERNAL WARD PHYSICIANS, DIABETES PHYSICIANS AND AN APPLICATION, FOR DIABETES PATIENTS DISCHARGED FROM HOSPITALIZATION IN AN INTERNAL WARD].

Wainstein J, Luzovetsky G, Auerbach H, Raz I.Harefuah. 2021 Oct;160(10):663-667.PMID: 34689436 Hebrew.

 

418. [HEMOGLOBIN A1C AND MORTALITY FROM COVID-19].

Merzon E, Green I, Shpigelman M, Vinker S, Raz I, Golan-Cohen A, Eldor R.Harefuah. 2021 Oct;160(10):645-650.PMID: 34689433 Hebrew.

 

419. [DIABETES - PRESENT AND FUTURE].

Raz I.Harefuah. 2021 Oct;160(10):634-637.PMID: 34689431 Hebrew.

 

420. Adolescent cognitive function and incident early-onset type 2 diabetes.

Lutski M, Zucker I, Bardugo A, Bendor CD, Derazne E, Tzur D, Novick D, Raz I, Pinhas-Hamiel O, Mosenzon O, Afek A, Gerstein HC, Twig G, Cukierman-Yaffe T.EClinicalMedicine. 2021 Sep 24;41:101138. doi: 10.1016/j.eclinm.2021.101138. eCollection 2021 Nov.PMID: 34622185 Free PMC article.

 

 

 

421. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.

Berg DD, Wiviott SD, Scirica BM, Zelniker TA, Goodrich EL, Jarolim P, Mosenzon O, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Langkilde AM, Raz I, Braunwald E, Sabatine MS, Morrow DA.Diabetes Care. 2021 Nov;44(11):2573-2581. doi: 10.2337/dc21-1170. Epub 2021 Sep 17.PMID: 34535469

 

 

422. Myopia and Early Onset Type 2 Diabetes: A Nationwide Cohort Study.

Peled A, Raz I, Zucker I, Derazne E, Megreli J, Pinhas-Hamiel O, Einan-Lifshitz A, Morad Y, Pras E, Lutski M, Cukierman-Yaffe T, Mosenzon O, Tzur D, Tirosh A, Gerstein HC, Afek A, Twig G.J Clin Endocrinol Metab. 2021 Sep 10:dgab669. doi: 10.1210/clinem/dgab669. Online ahead of print.PMID: 34505129

 

423. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.

Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Park KS, Goudev A, Diaz R, Špinar J, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD.Eur Heart J. 2021 Aug 24:ehab530. doi: 10.1093/eurheartj/ehab530. Online ahead of print.PMID: 34427295

 

424. Management of diabetic neuropathy.

Cernea S, Raz I.Metabolism. 2021 Oct;123:154867. doi: 10.1016/j.metabol.2021.154867. Epub 2021 Aug 17.PMID: 34411554 Review.

 

Editor-Books

    1.   Diabetes in the Third Millennium, Published by the Israel Diabetes Association, Tel-   Aviv, 2002

2.    M. Dunitz - Diabetes: From Research to Diagnosis and Treatment. Edited by Raz I, Skyler J and Shafrir E.  Published by M. Dunitz, Taylor and Francis Associates U.K. 2002.

 

Chapters in Books:

1.       Michaeli JU, Lugassy G, Raz I, Polliack A. Chronic lymphocytic leukemia. Chapter 17. A. Polliack, and D. Catovsky, editors, Harwood Academic Publishers. London - New York, pp. 231-248,  1988

2.       Flyvbjerg A,  Landau D,  Klien W,  Bondy C,  Chine E,  Raz I, Phillip M,  Leroith D. The role of insulin-like growth factors (IGFS) and IGF binding protein in diabetic nephropathy. Proceedings of the 15th International Diabetes Federation. 1995.

3.       Raz I, Wexler ID. Extra-renal complications of the type 2 diabetic patient with diabetic nephropathy. In: Nephropathy in Type 2 Diabetes. Ritz, E., Flisher, D. (eds.) London: Oxford University. Publisher Oxford New York Oxford University Press 1999. 

4.       Guest Editor: Diabetes-inevitable or preventable?  Diabetes-Obesity-Metabolism 3: (supl 1)1-    43, 2001.

5.        Khamaisi M, Symmer L, Raz I. Thiazolidinediones in cardiovascular risk in type 2 diabetes mellitus. In: Cardiovascular risk in type 2 diabetes: assessment and control. Edited by Nicolae Hancu, Springer-Verlag GmBH, New York ,pp. 193-203, 2002

6.       Khamaisi M, Wexler I, Raz I. Cardiovascular disease in type 2 diabetes. In: Diabetes: From Research to Diagnosis and Treatment. Edited by I. Raz, E. Shafrir published by M. Dunitz, Taylor and Francis Associates U.K 2002.

 

7.       Cernea S., Cahn A., Raz I. Glycemic Targets and Prevention of Chronic Complications. In: Bonora E., DeFronzo R. (eds) Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Endocrinology. Springer, Cham (2018)

 

 

8.       Cahn A, Endevelt R, Raz I. Prevention of diabetes in Israel. In Global Health Perspectives in Prediabetes and Diabetes Prevention. Bergman M. ed. Wiley-Blackwell. (2014). Chapter 16 pp 365-390.

 

9.        Cahn A, Raz I, Itzhak B. Practical approach to the implementation of diabetes prevention. In Diabetes Prevention - from Science to Practice. P. Schwarz, ed. Wiley-Blackwell. (2012). Chapter 13 pp 195-207.

 

 

10.    Cahn A, Raz I. Relation of Hemoglobin A1c to restenosis after PCI. Proceedings of the 9th International Congress on Coronary Artery Disease. October 2011 pp 303-306.

bottom of page